Multi-Drug X(2-20) Drugs Rapid Test Panel with/without Adulteration (Urine)

Package Insert

Instruction Sheet for testing of any combination of the following drugs: ACE/AMP/BAR/BZO/BUP/COC/THC/MTD/MET/MDMA/MOP/MQL/OPI/PCP/PPX/TCA/TML/KET/OXY/COT/EDDP/FYL/K2/6-MAM/MDA/ETG/CLO/LSD/MPD/ZOL/MEP/MDPV/DIA/ZOP/MCAT/T-ACL/CAF/CFYL/CAT/TRO/ALP/PGB/ZAL/MPRD/CNB/GAB/TZD/CAR/ABP(K3)/QTP/FLX/UR-144(K4)/KRA/TLD/α-PVP/MES/PAP/CIT/FKET/OZP/RPD/TAP/NND/SCOP/MTZ/HMO/ALC

Including Specimen Validity Tests (S.V.T.) for:

Oxidants/PCC, Specific Gravity, pH, Nitrite, Glutaraldehyde, Creatinine and Bleach

A rapid test for the simultaneous, qualitative detection of multiple drugs and drug metabolites in human urine. For healthcare professionals including professionals at point of care sites. Immunoassay for in vitro diagnostic use only.

[INTENDED USE]

The Multi-Drug Rapid Test Panel is a rapid chromatographic immunoassay for the qualitative detection of multiple drugs and drug metabolites in human urine at the following cut-off concentrations:

| Test | Calibrator | Cut-off (ng/mL) |
|--|--|-----------------------------|
| Acetaminophen (ACE) | Acetaminophen | 5,000 |
| Amphetamine (AMP) | d-Amphetamine | 1,000/500/300 |
| Barbiturates (BAR) | Secobarbital | 300/200 |
| Benzodiazepines (BZO) | Oxazepam | 500/300/200/100 |
| Buprenorphine (BUP) | Buprenorphine | 10/5 |
| Cocaine (COC) | Benzoylecgonine | 1,500/300/200/150/100 |
| Marijuana (THC) | 11-nor-Δ ⁹ -THC-9 COOH | 300/200/150/50/30/25/ 20 |
| Methadone (MTD) | Methadone | 300/200/100 |
| Methamphetamine (MET) | d-Methamphetamine | 1,000/500/300/200 |
| Methylenedioxyme- thamphetamine(MDMA) | d,l-Methylenedioxymethamphetamine | 1,000/500/300 |
| Morphine/Opiate (MOP/OPI) | Morphine | 300/200/100 |
| Methaqualone (MQL) | Methaqualone | 300 |
| Meperidine (MPRD) | Normeperidine | 100 |
| Opiate (OPI) | Morphine | 2,000/1,000 |
| Phencyclidine (PCP) | Phencyclidine | 50/25 |
| Propoxyphene (PPX) | Propoxyphene | 300 |
| Tricyclic Antidepressants (TCA) | Nortriptyline | 1,000/500/300 |
| Tramadol (TML) | Cis-Tramadol | 500/300/200/100 |
| Ketamine (KET) | Ketamine | 1,000/500/300/100 |
| Oxycodone (OXY) | Oxycodone | 300/100 |
| Cotinine (COT) | Cotinine | 500/300/200/100/50/10 |
| 2-ethylidene-1,5-dimethyl- | 2-ethylidene-1,5-dimethyl- | 200/400 |
| 3,3-diphenylpyrrolidine (EDDP) | 3,3-diphenylpyrrolidine | 300/100 |
| Fentanyl (FYL) | Norfentanyl | 20/10 |
| Fentanyl (FYL) | Fentanyl | 300/200/100 |
| Synthetic Marijuana (K2) | JWH-018、JWH-073 | 50/30/25 |
| 6-Monoacetylmorphine (6-MAM) | 6-MAM | 10 |
| (±) 3,4-Methylenedioxy- Amphetamine (MDA) | (±) 3,4-Methylenedioxy- Amphetamine | 500 |
| Ethyl- β-D-Glucuronide (ETG) | Ethyl- β -D-Glucuronide | 1,500/1,000/500/300 |
| Clonazepam (CLO) | Clonazepam | 400/150 |
| Lysergic Acid Diethylamide (LSD) | Lysergic Acid Diethylamide | 50/20/10 |
| Methylphenidate (MPD) | Methylphenidate | 300/150 |
| Methylphenidate (MPD) | Ritalin acid | 1,000 |
| Zolpidem (ZOL) | Zolpidem | 50/25 |
| Mephedrone (MEP) | Mephedrone | 500/100 |
| 3, 4-methylenedioxy- | · | |
| pyrovalerone (MDPV) | 3, 4-methylenedioxypyrovalerone | 1,000/500/300 |
| Diazepam (DIA) | Diazepam | 300/200 |
| Zopiclone (ZOP) | Zopiclone | 300/50 |
| Methcathinone (MCAT) | S(-)-Methcathinone | 500 |
| . , | | |

| 7-Aminoclonazepam (7-ACL) | 7-Aminoclonazepam | 300/200/100 |
|--|--------------------------------|---------------------|
| Carfentanyl (CFYL) | Carfentanyl | 500/250 |
| Cannabinol (CNB) | Cannabinol | 500 |
| Caffeine (CAF) | Caffeine | 1.000 |
| Cathine (CAT) | (+)-Norpseudoephedrine | 150 |
| Tropicamide (TRO) | Tropicamide | 350 |
| Alprazolam (ALP) | Alprazolam | 100 |
| Pregabaline (PGB) | Pregabaline | 50,000/500 |
| Gabapentin (GAB) | Gabapentin | 2,000 |
| Zaleplon (ZAL) | Zaleplon | 100 |
| Carisoprodol (CAR) | Carisoprodol | 2,000/1,000/500 |
| AB-PINACA/K3 (ABP/K3) | AB-PINACA | 10 |
| Quetiapine (QTP) | Quetiapine | 1,000 |
| Fluoxetine (FLX) | Fluoxetine | 500 |
| UR-144/K4 | UR-144 5-Pentanoic acid | 25 |
| Kratom (KRA) | Mitragynine | 300 |
| Tilidine (TLD) | Nortilidine | 50 |
| Trazodone (TZD) | Trazodone | 200 |
| Alpha-Pyrrolidinovalerophenone (α-PVP) | Alpha-Pyrrolidinovalerophenone | 2,000/1,000/500/300 |
| Mescaline (MES) | Mescaline | 300/100 |
| Papaverine (PAP) | Papaverine | 500 |
| Citalopram (CIT) | Citalopram | 500 |
| Fluoketamine (FKET) | Fluoketamine | 1,000 |
| Olanzapine (OZP) | Olanzapine | 1,000 |
| Risperidone (RPD) | Risperidone | 150 |
| Tapentadol (TAP) | Tapentadol | 1,000 |
| N,N-Dimethyltryptamine (NND) | N,N-Dimethyltryptamine | 1,000 |
| Scopolamine (SCOP) | Scopolamine | 500 |
| Mirtazapine (MTZ) | Desmethylmirtazapine | 500 |
| Hydromorphone (HMO) | Hydromorphone | 500/300/250 |
| Test | Calibrator | Cut-off |
| Alcohol(ALC) | Alcohol | 0.02% |
| <u> </u> | · | |

Configurations of the Multi-Drug Rapid Test Panel come with any combination of the above listed drug analytes with or without S.V.T. This assay provides only a preliminary test result. A more specific alternate chemical method must be used in order to obtain a confirmed analytical result. Gas Chromatography/Mass Spectrometry (GC/MS) is the preferred confirmatory method. Clinical consideration and professional judgment should be applied to any drug of abuse test result, particularly when preliminary positive results are indicated.

[SUMMARY OF ADULTERATION]

Adulteration is the tampering of a urine specimen with the intention of altering the test results. The use of adulterants can cause false negative results in drug tests by either interfering with the screening test and/or destroying the drugs present in the urine. Dilution may also be employed in an attempt to produce false negative drug test results.

One of the best ways to test for adulteration or dilution is to determine certain urinary characteristics such as pH, specific gravity and creatinine and to detect the presence of oxidants/PCC, nitrites or glutaraldehyde in urine.

[PRINCIPLE (FOR DOA TESTS EXCLUDING ALCOHOL)]

During testing, a urine specimen migrates upward by capillary action. A drug, if present in the urine specimen below its cut-off concentration, will not saturate the binding sites of its specific antibody. The antibody will then react with the drug-protein conjugate and a visible colored line will show up in the test region of the specific drug dipstick. The presence of drug above the cut-off concentration will saturate all the binding sites of the antibody. Therefore, the colored line will not form in the test region.

A drug-positive urine specimen will not generate a colored line in the specific test region of the dipstick because of drug competition, while a drug-negative urine specimen will generate a line in the test region because of the absence of drug competition.

To serve as a procedural control, a colored line will always appear at the control region, indicating that proper volume of specimen has been added and membrane wicking has occurred.

[PRINCIPLE OF ADULTERATION]

Oxidants/PCC (Pyridiniumchlorochromate) tests for the presence of oxidizing agents such as bleach and hydrogen peroxide. Pyridiniumchlorochromate (sold under the brand name Urine Luck) is a commonly used adulterant. Normal human urine should not contain oxidants of PCC.

Specific gravity tests for sample dilution. The normal range is from 1.003 to 1.030. Values outside this range may be the result of specimen dilution or adulteration.

pH tests for the presence of acidic or alkaline adulterants in urine. Normal pH levels should be in the range of 4.0 to 9.0. Values outside of this range may indicate the sample has been altered

Nitrite tests for commonly used commercial adulterants such as Klear and Whizzies. They work by oxidizing the major cannabinoid metabolite THC-COOH.³ Normal urine should contain no trace of nitrite. Positive results generally indicate the presence of an adulterant.

Glutaraldehyde tests for the presence of an aldehyde. Adulterants such as Urin Aid and Clear Choice contain glutaraldehyde which may cause false negative results by disrupting the enzyme used in some immunoassay tests.³ Glutaraldehyde is not normally found in urine; therefore, detection of glutaraldehyde in a urine specimen is generally an indicator of adulteration.

Creatinine is a waste product of creatine; an amino-acid contained in muscle tissue and found in urine. A person may attempt to foil a test by drinking excessive amounts of water or diuretics such as herbal teas to flush the system. Creatinine and specific gravity are two ways to check for dilution and flushing, which are the most common mechanisms used in an attempt to circumvent drug testing. Low Creatinine and specific gravity levels may indicate dilute urine. The absence of Creatinine (<5 mg/dL) is indicative of a specimen not consistent with human urine.

Bleach tests for the presence of bleach. Bleach refers to a number of chemicals which remove color, whiten or disinfect, often by oxidation, Bleaches are used as household chemicals to whiten clothes and remove stains and as disinfectants. Normal human urine should not contain bleach

[PRINCIPLE (FOR ALCOHOL)]

The urine Alcohol Rapid Test Panel consists of a plastic strip with a reaction pad attached at the tip. On contact with alcohol, the reaction pad will change colors depending on the concentration of alcohol present. This is based on the high specificity of alcohol oxidase for ethyl alcohol in the presence of peroxidase and enzyme substrate such as TMB.

[REAGENTS(FOR DOA TESTS EXCLUDING ALCOHOL)]

Each test line contains anti-drug mouse monoclonal antibody and corresponding drug-protein conjugates. The control line contains goat anti-rabbit IgG polyclonal antibodies and rabbit IgG.

[REAGENTS (FOR ALCOHOL)]

Tetramethylbenzidine, Alcohol Oxidase, Peroxidase

[S.V.T REAGENTS]

| Adulteration Pad | Reactive indicator | Buffers and non-reactive ingredients |
|------------------|--------------------|--------------------------------------|
| Creatinine | 0.04% | 99.96% |
| Nitrite | 0.07% | 99.93% |
| Bleach | 0.39% | 99.61% |
| Glutaraldehyde | 0.02% | 99.98% |
| рН | 0.06% | 99.94% |
| Specific Gravity | 0.25% | 99.75% |
| Oxidants / PCC | 0.36% | 99.64% |

[PRECAUTIONS]

- For healthcare professionals including professionals at point of care sites.
- Immunoassay for in vitro diagnostic use only. The test should remain in the sealed pouch until use.
- All specimens should be considered potentially hazardous and handled in the same manner as an infectious agent.
- The used test should be discarded according to local regulations.

STORAGE AND STABILITY

Store as packaged in the sealed pouch at 2-30°C. The test is stable through the expiration date printed on the sealed pouch. The Test must remain in the sealed pouch until use. **DO NOT FREEZE**. Do not use beyond the expiration date.

[SPECIMEN COLLECTION AND PREPARATION]

Urine Assav

The urine specimen should be collected in a clean and dry container. Urine collected at any time of the day may be used. Urine specimens exhibiting visible precipitates should be centrifuged, filtered, or allowed to settle to obtain a clear specimen for testing.

Specimen Storage

Urine specimens may be stored at 2-8°C for up to 48 hours prior to testing. For prolonged storage, specimens may be frozen and stored below -20°C. Frozen specimens should be thawed and mixed well before testing. When testing cards with S.V.T. or Alcohol storage of urine specimens should not exceed 2 hours at room temperature or 4 hours refrigerated prior to testing.

[MATERIALS]

Test Panels

Materials Provided

- Package Insert
- · Adulteration Color Chart (when applicable)


Materials Required But Not Provided

Timer · Specimen collection containers


[DIRECTIONS FOR USE]

Allow the test, urine specimen and/or controls to reach room temperature (15-30°C) prior

- 1. Bring the pouch to room temperature before opening it. Remove the test panel from the sealed pouch and use it within one hour.
- Remove the cap.
- 3. With the arrow pointing toward the urine specimen, immerse the test panel vertically in the urine specimen for at least 10 to 15 seconds. Immerse the dipstick to at least the level of the wavy lines, but not above the arrow on the test panel.
- 4. Replace the cap and place the test panel on a non-absorbent flat surface.
- 5. Start the timer and wait for the colored line(s) to appear.
- 6. Read the adulteration strips and alcohol strip between 3-5 minutes according to color chart provided separately/on foil pouch. Refer to your Drug Free Policy for guidelines on adulterated specimens. We recommend not to interpret the drug test results and either retest the urine or collect another specimen in case of any positive result for any adulteration test.
- 7. The drug strip result should be read at 5 minutes. Do not interpret the result after 10 minutes.



Interpret adulteration strips and alcohol strip between 3-5 minutes. See enclosed



[INTERPRETATION OF RESULTS]

(Please refer to the illustration above)

NEGATIVE:* A colored line appears in the control region (C) and another colored line appears in the test region (T). This negative result means that the concentrations in the urine sample are below the designated cut-off levels for a particular drug tested.

*NOTE: The shade of the colored lines(s) in the test region (T) may vary. The result should be considered negative whenever there is even a faint line.

POSITIVE: A colored line appears in the control region (C) and no line appears in the test region (T). The positive result means that the drug concentration in the urine sample is greater than the designated cut-off for a specific drug.

INVALID: No line appears in the control region (C). Insufficient specimen volume or incorrect procedural techniques are the most likely reasons for control line failure. Read the directions again and repeat the test with a new test. If the result is still invalid, contact your manufacturer.

[INTERPRETATION OF RESULTS (S.V.T/ ADULTERATION)]

(Please refer to the color chart)

Semi-Quantitative results are obtained by visually comparing the reacted color blocks on the strip to the printed color blocks on the color chart. No instrumentation is required.

[INTERPRETATION OF RESULTS (ALCOHOL STRIP)]

Negative: Almost no color change by comparing with the background. The negative result indicates that the urine alcohol level is less than 0.02%.

Positive: A distinct color developed all over the pad. The positive result indicates that the urine alcohol concentration is 0.02% or higher.

Invalid: The test should be considered invalid if only the edge of the reactive pad turned color that might be ascribed to insufficient sampling. The subject should be re-tested. Besides, if the color pad has a blue color before applying urine sample, do not use the test.

[QUALITY CONTROL]

A procedural control is included in the test. A line appearing in the control region (C) is considered an internal procedural control. It confirms sufficient specimen volume, adequate membrane wicking and correct procedural technique.

Control standards are not supplied with this kit. However, it is recommended that positive and negative controls be tested as good laboratory practice to confirm the test procedure and to verify proper test performance.

[LIMITATIONS]

- 1. The Multi-Drug Rapid Test Panel provides only a qualitative, preliminary result. A secondary analytical method must be used to obtain a confirmed result. Gas Chromatography /Mass Spectrometry (GC/MS) is the preferred confirmatory method. 4,5
- 2. There is a possibility that technical or procedural errors, as well as interfering substances in the urine specimen may cause erroneous results.
- 3. Adulterants, such as bleach and/or alum, in urine specimens may produce erroneous results regardless of the analytical method used. If adulteration is suspected, the test should be repeated with another urine specimen.
- 4. A positive result does not indicate level or intoxication, administration route or concentration
- 5. A negative result may not necessarily indicate drug-free urine. Negative results can be obtained when drug is present but below the cut-off level of the test.
- 6. This test does not distinguish between drugs of abuse and certain medications.
- 7. A positive test result may be obtained from certain foods or food supplements.

(S.V.T/ ADULTERATION LIMITATIONS)

- 1. The adulteration tests included with the product are meant to aid in the determination of abnormal specimens. While comprehensive, these tests are not meant to be an "all-inclusive" representation of possible adulterants.
- 2. Oxidants/PCC: Normal human urine should not contain oxidants or PCC. The presence of high levels of antioxidants in the specimen, such as ascorbic acid, may result in false negative results for the oxidants/PCC pad.
- 3. Specific Gravity: Elevated levels of protein in urine may cause abnormally high specific
- 4. Nitrite: Nitrite is not a normal component of human urine. However, nitrite found in urine may indicate urinary tract infections or bacterial infections. Nitrite levels of >20 mg/dL may produce false positive glutaraldehyde results.
- 5. Glutaraldehyde: is not normally found in urine. However certain metabolic abnormalities such as ketoacidosis (fasting, uncontrolled diabetes or high protein diets) may interfere with the test results
- 6. Creatinine: Normal Creatinine levels are between 20 and 350 mg/dL. Under rare conditions, certain kidney diseases may show dilute urine.
- 7. Bleach: Normal human urine should not contain bleach. The presence of high levels of bleach in the specimen may result in false negative results for the bleach pad.
- 8. pH: Normal pH levels are between 4.0 and 9.0.

[PERFORMANCE CHARACTERISTICS]

% Agreement with GC/MS

| | ACE | AMP | AMP | AMP | BAR | BAR | BZO | BZO | BZO | BZO | BUP | | | |
|-----------------------|------------|-------|------------|-------|-------|-------|-------|-------|-------|-------|------------|--|--|--|
| | 5,000 | 1,000 | 500 | 300 | 300 | 200 | 500 | 300 | 200 | 100 | 10 | | | |
| Positive Agreement | 93.5% | 98.1% | 99.1% | 99.1% | 96.1% | 95.3% | 98.2% | 98.4% | 99.2% | 99.2% | 99.1% | | | |
| Negative Agreement | 98.6% | 97.9% | 98.6% | 98.5% | 98.6% | 97.9% | 97.8% | 99.2% | 98.4% | 97.5% | >99.9 % | | | |
| Total Results | 97.0% | 98.0% | 98.8% | 98.8% | 97.6% | 96.8% | 98.0% | 98.8% | 98.8% | 98.4% | 99.6% | | | |
| | | | | | | | | | | | | | | |
| | BUP | COC | COC | COC | COC | THC | THC | THC | THC | THC | MTD | | | |
| | 5 | 300 | 200 | 150 | 100 | 300 | 150 | 50 | 25 | 20 | 300 | | | |
| Positive Agreement | 99.1% | 98.2% | >99.9 % | 98.3% | 99.2% | 95.5% | 94.5% | 97.9% | 96.9% | 94.8% | 98.9% | | | |
| Negative Agreement | >99.9 % | 97.8% | >99.9 % | 97.0% | 97.0% | 98.1% | 97.5% | 98.1% | 97.4% | 99.3% | 98.8% | | | |
| Total Results | 99.6% | 98.0% | 100.0 | 97.6% | 98.0% | 97.2% | 96.4% | 98.0% | 97.2% | 97.6% | 98.8% | | | |

| | MTD 200 | MET 1,000 | MET 500 | MET 300 | MDMA 1,000 | MDMA 500 | MDMA 300 | MOP/ OPI 300 | MOP/ OPI 100 | MQL 300 | OPI 2,000 |
|--------------------------------|------------------------|---------------------|---------------------|---------------|---------------|--------------|-------------|--------------------|--------------------|--------------|--------------------------------|
| Positive Agreement | 98.9% | 96.2% | 97.6% | 97.8% | 98.0% | 98.1% | 98.1% | 95.0% | 97.0% | 89.8% | 96.7% |
| Negative Agreement | 98.7% | 97.1% | 97.0% | 97.5% | 99.3% | 99.3% | 99.3% | 95.3% | 96.6% | 93.2% | 93.8% |
| Total Results | 98.8% | 96.8% | 97.2% | 97.6% | 98.8% | 98.8% | 98.8% | 95.2% | 96.8% | 92.0% | 95.2% |
| | | | | | | | | | | | |
| 1 | PCP 25 | PPX 300 | TCA 1,000 | TCA 500 | TML 100 | TML 200 | TML 300 | 1,000 | KET 500 | KET 300 | 100 |
| Positive Agreement | 92.4% | 96.0% | 94.8% | 94.9% | | 88.2% | 88.0% | 97.5% | 97.6% | 96.7% | 96.0% |
| Negative Agreement | 96.8% | 94.0% | 91.6% | 92.1% | 92.4% | 96.2% | 96.2% | 98.2% | 98.2% | 97.5% | 97.3% |
| Total Results | 95.2% | 94.8% | 92.8% | 93.2% | 90.8% | 93.2% | 93.2% | 98.0% | 98.0% | 97.2% | 96.8% |
| | | | | | | | | | | | |
| ı | OXY | OXY | COT | COT | COT | COT | COT | EDDP | EDDP | FYL | FYL |
| Dealthire | 100 | 300 | 500 | 200 | 100 | 50 | 10 | 300 | 100 | 20 | 10 |
| Positive Agreement | 97.7% | 96.5% | 95.7% | 96.7% | 97.9% | 96.7% | 97.8% | 97.9% | 96.9% | 98.8% | 98.8% |
| Negative Agreement Total | 99.4% | 99.4% | 96.1% | 97.5% | 98.1% | 97.5% | 98.1% | 99.4% | 96.7% | 99.4% | 99.4% |
| Results | 98.8% | 98.4% | 96.0% | 97.2% | 98.0% | 97.2% | 98.0% | 98.8% | 96.8% | 99.2% | 99.2% |
| | K2 | K2 | 6-MAM | MDA | ETG | ETG | CLO | CLO | LSD | LSD | LSD |
| | 50 | 30 | 10 | 500 | 500 | 1,000 | 400 | 150 | 10 | 20 | 50 |
| Positive Agreement | 97.5% | 97.6% | 97.7% | 98.1% | 97.6% | 95.3% | 97.1% | 99.0% | 94.3% | 94.3% | 94.1% |
| Negative Agreement | 98.2% | 98.8% | 98.1% | 97.9% | 99.4% | 99.4% | 99.3% | 98.6% | 98.5% | 98.5% | 98.5% |
| Total Results | 98.0% | 98.4% | 98.0% | 98.0% | 98.8% | 98.0% | 98.4% | 98.8% | 97.0% | 97.0% | 97.0% |
| | 1 | | 1 | | | | | | 1 | | |
| | MPD 300 | MPD 1,000 | ZOL 50 | DIA 300 | DIA 200 | ZOP 50 | MCAT 500 | 7-ACL 300 | 7-ACL 200 | 7-ACL 100 | CFYL 500 |
| Positive Agreement | 94.6% | 94.6% | 90.9% | 98.4% | 98.4% | 86.4% | 90.9% | 94.1% | 94.6% | 94.7% | 94.7% |
| Negative Agreement | 98.4% | 98.4% | 97.1% | 99.2% | 99.2% | 97.2% | 95.0% | 97.7% | 97.6% | 97.5% | 98.6% |
| Total Results | 97.0% | 97.0% | 95.6% | 98.8% | 98.8% | 94.6% | 94.1% | 96.2% | 96.2% | 96.2% | 97.3% |
| | 045 | OAT | TDO | MDDV | MDDV | MED | AL D | ADD/ | -: D\/D | OND | MDDE |
| i | CAF 1,000 | 150 | TRO 350 | MDPV 1,000 | MDPV 500 | MEP 100 | ALP 100 | ABP/ K3-10 | α-PVP 1,000 | CNB 500 | MPRE 100 |
| Positive Agreement | 91.3% | 90.5% | 92.0% | 93.3% | 93.1% | 90.5% | 90.9% | 92.0% | 92.1% | 95.8% | 95.0% |
| Negative Agreement | 95.7% | 97.3% | 97.0% | 98.6% | 98.3% | 97.0% | 97.4% | 97.1% | 96.8% | 97.6% | 94.2% |
| Total | | | | 97.0% | 96.6% | 95.4% | 95.9% | 95.8% | 95.0% | 96.9% | 94.4% |
| Results | 94.6% | 95.8% | 95.6% | 97.0% | 30.070 | | | | | | |
| | 94.6% | 95.8% | 95.6% | 97.0% | 30.070 | | l | | | | |
| | 94.6% PGB 50,000 | 95.8% TZD 200 | UR- 144/K4 | 7AI | MES 100 | GAB 2,000 | MOP/ OPI | ETG 300 | α-PVP 500 | TLD 50 | |
| Results | PGB | TZD | UR- | ZAL | MES | | | | | | 1,000 |
| Results | PGB 50,000 | TZD 200 | UR- 144/K4 25 | ZAL 100 | MES 100 | 2,000 | OPI 200 | 300 | 500 | 50 | QTP 1,000 97.1% 98.3% |

| | PAP | KRA | CAR | | LX | K | | CI | | FKE | | RPD | | FYL | FYL | CFYL |
|-----------------------|---------|--------|---------|--------|----------|------|-------|------|----------|-------|------|-------|-----|-------|---------|----------|
| | 500 | 300 | 2,000 | 5 | 00 | 2 | 5 | 50 | 0 | 1,00 | 00 | 150 | 4 | 100 | 200 | 250 |
| Positive | 96.9% | 95.7% | 95.0% | 97 | .1% | 97.6 | 6% | 93.3 | 3% | 96.7 | % | 93.39 | 6 9 | 8.8% | 97.5% | 94.7% |
| Agreement Negative | | | | | | | | | | | + | | + | | | |
| Agreement | 98.0% | 98.3% | 94.2% | 96 | .6% | 98.2 | 2% | 95.5 | 5% | 97.0 | % ! | 95.59 | 6 9 | 9.4% | 99.4% | 98.6% |
| Total | 07.00/ | 07.00/ | 0.4.407 | | 00/ | | 201 | | 201 | 00.0 | ۵, ۱ | | , , | 0.00/ | 00.00/ | 07.00/ |
| Results | 97.6% | 97.6% | 94.4% | 96 | .8% | 98.0 | 0% | 94.8 | 3% | 96.9 | % ! | 94.89 | % 9 | 9.2% | 98.8% | 97.3% |
| | | | | | | | | | | | | | | | | |
| | PGB | MES | | | MDP | | α-P\ | | | PVP | | AP | | IND | SCOP | MTZ |
| | 500 | 300 | 1,00 | 00 | 300 |) | 2,00 | 00 | 3 | 800 | 1, | 000 | 1. | ,000 | 500 | 500 |
| Positive | 95.2% | 95.89 | 6 95.8 | % | 93.89 | % | 86.8 | 3% | 92 | .1% | 94 | .4% | 96 | 6.7% | 93.5% | 93.3% |
| Agreement Negative | | 1 | | - | | + | | | | | | | - | | | |
| Agreement | 96.3% | 97.69 | 6 97.6 | % | 97.19 | % | 96.8 | 3% | 95 | .2% | 98 | .2% | 97 | 7.0% | 98.6% | 95.6% |
| Total | | | | | | | | | | | | | | | | |
| Results | 96.0% | 96.9% | 6 96.9 | % | 96.19 | % | 93.0 |)% | 94 | .0% | 96 | .7% | 96 | 6.9% | 97.0% | 94.9% |
| | | | | | | | | | | | | | | | | |
| | COT | THC | THC | N | 1EP | М | PD | C | PI | P | СР | ΤN | 1L | TCA | CAR | FYL |
| | 300 | 200 | 30 | 5 | 500 | 1 | 50 | 1, | 000 |) 5 | 50 | 50 | 0 | 300 | 1,000 | 300 |
| Positive | 97.7% | 93.4% | 97.9% | 95 | 5.2% | 91 | .9% | 95 | .9% | 6 92 | .3% | 92.9 | 9% | 94.99 | % 90.0% | 97.0% |
| Agreement | | | | 1 | | - | | - | | + | | 1 | | | + | \vdash |
| Negative Agreement | 97.5% | 97.5% | 98.1% | 98 | 3.5% | 98 | .4% | 93 | .8% | 6 96 | .9% | 98. | 1% | 92.19 | % 98.1% | 98.9% |
| Total | | | | 1 | | | | | | + | | 1 | | | | |
| Results | 97.6% | 96.0% | 98.0% | 0% 97. | | 96 | .0% | 94 | .8% | 6 95 | .2% | 96.9 | 9% | 93.29 | % 95.8% | 98.6% |
| | | | | | | | | | | | | | | | | |
| | HMC |) HM | ОН | MO | M | IET | (| CAR | 2 | COC |) | ETG | 7 | ZOP | ZOL | MTD |
| | 250 | 300 | 5 | 00 | 2 | 00 | | 500 | | 1,50 | 0 ′ | ,500 |) : | 300 | 25 | 100 |
| Positive | 93.89 | % 91.7 | % 91 | .7% | 97 | .6% | , 9 | 0.09 | % | 92.09 | % 9 | 7.7% | 9 | 0.9% | 90.9% | 98.9% |
| Agreement | | - | | , . | <u> </u> | | Ļ | | - | | - | | Ť | | | |
| Negative | 97.59 | % 98.7 | % 98 | .7% | 97 | .0% | 9 | 2.39 | % | 98.39 | % 9 | 9.4% | 9 | 7.2% | 97.1% | 98.7% |
| Agreement | | | | | 1 | | + | | + | | + | | + | | | |
| Total Result | s 96.19 | % 96.1 | % 96 | .1% | 97 | .2% | 9 | 1.79 | % | 95.29 | % 9 | 8.8% | 9 | 5.7% | 95.6% | 98.8% |
| | | | | | | | | | | | | | | | | |
| | | | % A | gree | men | t wi | ith C | om | me | rcial | Kit | | | | | |
| | ACE | AMF | | | ΒZ | | ΒL | | | OC | C | OC | TI | HC | THC | MPD |
| | 5,000 | | | | 50 | | 10 | /5 | | 00/ | | | |)/50/ | 300/ | 1,000/ |
| | | 500 | | 00 | 30 | | | | 1 | 00 | | 00/ | 2 | 25 | 200/30/ | 300/ |
| | | 300 | ' | | 20 10 | | | | | | 1 | 50 | | | 20 | 150 |
| Positive | 1 | + | | | | | | | \vdash | | - | | | | | |
| Agreement | * | >99.9 | %>99 | .9% | >99. | 9% | >99 | .9% | >9 | 9.9% | | * | >99 | .9% | * | * |
| Negative | | | 0/ 0- | 00/ | 0.5 | 201 | | 00: | | 0.001 | | * | | | * | * |
| Agreement | * | >99.9 | %>99 | .9% | >99. | 9% | >99 | .9% | >9 | 9.9% | L | * | >99 | .9% | * | * |
| Total Result | s * | >99.9 | %>99 | .9% | >99. | 9% | >99 | .9% | >9 | 9.9% | | * | >99 | .9% | * | * |
| | | | | | | | | | | | | | | | | |
| | 7-AC | L MT |) MI | ĒΤ | ME | T | MD | MA | MI | DMA | M | /PC | М | QL | MEP | LSD |
| | 300/ | | | 00/ | 20 | 0 | 1,0 | | 3 | 300 | | PI | 3 | 00 | 500/ | 50/20/ |
| | 200/ | | | 0/ | | | 50 | 00 | | | | 00/ | | | 100 | 10 |
| | 100 | 100 | 30 | 00 | | | | | | | | 00/ | | | | |
| Docitives | | + | _ | | | | | | - | | 1 | 00 | | | | |
| Positive Agreement | * | >99.9 | >99 | .9% | * | | >99 | .9% | | * | >99 | 9.9% | >99 | 9.9% | * | * |
| Negative | + | + | | | | - | | | <u> </u> | | | | | | | |
| Agreement | * | >99.9 | >99 | .9% | * | | >99 | .9% | | * | >99 | 9.9% | >99 | 9.9% | * | * |
| Total Result | s * | >99.9 | % >99 | .9% | * | | >99 | .9% | T | * | >99 | 9.9% | >99 | 9.9% | * | * |
| | | | | | | | | | | | | | | | | |

| | DD): | TC: | | . | <u>.</u> T | 00- | _ | 0.01 | _ | | _ | | 514 | 1405: |
|-----------------------|---------|----------|---------------|--------|------------|-------------|-----|------------|---|------|------------|-------|--------|-------|
| | PPX | TCA | | | | COT | | OPI | | CP | | CP | DIA | MDPV |
| | 300 | 1,000 | | | | 500/ | | 2,000/ | | 50 | | 25 | 300/ | 1,000 |
| | | 500/ | | | | 300/ | | 1,000 | | | | | 200 | 500/ |
| | | 300 | | | | 200/ | | | | | | | | 300 |
| | | | 100 |) 10 | 00 1 | 100/5 10 |)/ | | | | | | | |
| Positive | >99.9% | * | * | >99. | 9% | * | | * | | * | \ 9 | 9.9% | * | * |
| Agreement | - 00.07 | | _ | - 00. | .0 ,0 | | _ | | | | - 0 | 0.070 | | |
| Negative Agreement | >99.9% | * | * | >99 | .9% | * | | * | | * | >9 | 9.9% | * | * |
| Total Results | >99.9% | 6 * | * | >99. | .9% | * | | * | | * | >9 | 9.9% | * | * |
| | | | | | | | | | | | | | | |
| | OXY | EDDP | FYL | K2-50/ | | | 1DA | | | CLC | | ZOL | ZOP | MCAT |
| | 300/ | 300/ | 300/ | 30/25 | 10 |) | 500 | 1,50 | | 400 | | 50/25 | 300/50 | 500 |
| | 100 | 100 | 200/ | | | | | 1,00 | | 150 |) | | | |
| | | | 100/20 /10 | | | | | 500 300 | | | | | | |
| Positive | * | * | * | * | * | | * | * | | * | t | * | * | * |
| Agreement | Ŷ | • | _ | _ | Î | | • | _ | | • | | • | _ | ^ |
| Negative | * | * | * | * | * | | * | * | | * | | * | * | * |
| Agreement | Ŷ | • | _ | _ | Î | | • | _ | | • | | • | _ | ^ |
| Total Results | * | * | * | * | * | | * | * | | * | | * | * | * |
| | | | _ | | | | | | | | | | | |
| | CFYL | CAF | CAT | | - | ALP | | | | P/K3 | | NB | TZD | GAB |
| | 500/ | 1,000 | 150 | 35 | 0 | 100 | | 0,000/ | | 10 | 5 | 500 | 200 | 2,000 |
| | 250 | | | | | | + | 500 | | | | | | |
| Positive | * | * | * | * | | * | | * | | * | | * | * | * |
| Agreement | | | | - | | | + | | | | | | | |
| Negative | * | * | * | * | | * | | * | | * | | * | * | * |
| Agreement | * | * | * | * | _ | * | ┿ | * | | * | | * | * | * |
| Total Results | * | * | * | * | | | | * | | * | | * | * | * |
| | CAR | MPRE | QTF | FL | χI | JR-14 | 4 k | KRA | Т | LD | a- | PVP | MES | ZAL |
| | 2,000/ | 100 | 1,00 | | | K4-2 | | 300 | | 50 | | 000/ | 100/ | 100 |
| | 1,000/ | | 1,00 | | , | | | 000 | | | | 000/ | 300 | |
| | 500 | | | | | | | | | | | 00/ | 000 | |
| | 000 | | | | | | | | | | - | 300 | | |
| Positive | | * | * | * | + | * | + | * | | | F | * | | |
| Agreement | * | * | * | * | | * | | * | | * | | * | * | * |
| Negative | | | | | 1 | | 1 | | | | | | | |
| Agreement | * | * | * | * | | * | | * | | * | | * | * | * |
| otal Results | * | * | * | * | | * | T | * | | * | | * | * | * |
| | | | | I | | | | | | | | ı | I | |
| | CIT | FKET | RPD | TAF |) | NND | S | COP | M | ITZ | С | ZΡ | PAP | НМО |
| | 500 | 1,000 | 150 | 1,00 | | 1,000 | | 500 | | 00 | | 000 | 500 | 500/ |
| | | | 1 | 1 | | | 1 | | | | | | | |
| | J | | | | | | | | | | | J | | 300/ |
| | | | | | | | | | | | | | | |

| | CIT | FKET | RPD | TAP | NND | SCOP | MTZ | OZP | PAP | HMO |
|-----------|-----|-------|-----|-------|-------|------|-----|-------|-----|------|
| | 500 | 1,000 | 150 | 1,000 | 1,000 | 500 | 500 | 1,000 | 500 | 500/ |
| | | | | | | | | | | 300/ |
| | | | | | | | | | | 250 |
| Positive | * | * | * | * | * | * | * | * | * | * |
| Agreement | | | | | | | | | | |
| Negative | * | * | * | * | * | * | * | * | * | * |
| Agreement | | | | | | | | | | |
| Total | * | * | * | * | * | * | * | * | * | * |
| Results | | | | | | | | | | |

^{*}Note: Based on GC/MS data instead of Commercial Kit.

Precision

A study was conducted at three hospitals using three different lots of product to demonstrate the within run, between run and between operator precision. An identical card of coded specimens, containing drugs at concentrations of negative, 50% and 25% cut-off level, was labeled, blinded and tested at each site. The results gained ≧75% accuracy in ±25% cut-off level specimen and 100% accuracy in negative and ±50% cut-off level specimen.

Analytical Sensitivity

A drug-free urine pool was spiked with drugs at the listed concentrations. The results are summarized below.

| Drug Concentration Cut-off Range | A0 5,0 | | | /IP 000 | AN 50 | | | ИР 00 | B/ 30 | AR 00 | | AR 00 | B2 50 | | | ZO 00 |
|----------------------------------|-----------|----|----|------------|----------|----|----|----------|----------|----------|----|----------|----------|----|----|----------|
| Cut-off Range | - | + | - | + | - | + | - | + | - | + | - | + | - | + | - | + |
| 0% Cut-off | 30 | 0 | 30 | 0 | 30 | 0 | 30 | 0 | 30 | 0 | 30 | 0 | 30 | 0 | 30 | 0 |
| -50% Cut-off | 30 | 0 | 30 | 0 | 30 | 0 | 30 | 0 | 30 | 0 | 30 | 0 | 30 | 0 | 30 | 0 |
| -25% Cut-off | 26 | 4 | 26 | 4 | 25 | 5 | 27 | 3 | 27 | 3 | 26 | 4 | 27 | 3 | 27 | 3 |
| Cut-off | 14 | 16 | 15 | 15 | 15 | 15 | 15 | 15 | 15 | 15 | 15 | 15 | 15 | 15 | 15 | 15 |
| +25% Cut-off | 3 | 27 | 3 | 27 | 3 | 27 | 4 | 26 | 4 | 26 | 3 | 27 | 4 | 26 | 3 | 27 |
| +50% Cut-off | 0 | 30 | 0 | 30 | 0 | 30 | 0 | 30 | 0 | 30 | 0 | 30 | 0 | 30 | 0 | 30 |
| +300% Cut-off | 0 | 30 | 0 | 30 | 0 | 30 | 0 | 30 | 0 | 30 | 0 | 30 | 0 | 30 | 0 | 30 |

| Drug Concentration | | ZO 00 | | ZO 00 | | JP 0 | | JP 5 | | OC 500 | C(| | | OC 00 | C0 | DC 50 | | OC 00 |
|-----------------------|----|----------|----|----------|----|---------|----|---------|----|-----------|----|----|----|----------|----|----------|----|----------|
| Cut-off Range | - | + | - | + | - | + | - | + | - | + | - | + | - | + | - | + | - | + |
| 0% Cut-off | 30 | 0 | 30 | 0 | 30 | 0 | 30 | 0 | 30 | 0 | 30 | 0 | 30 | 0 | 30 | 0 | 30 | 0 |
| -50% Cut-off | 30 | 0 | 30 | 0 | 30 | 0 | 30 | 0 | 30 | 0 | 30 | 0 | 30 | 0 | 30 | 0 | 30 | 0 |
| -25% Cut-off | 27 | 3 | 27 | 3 | 26 | 4 | 26 | 4 | 25 | 5 | 26 | 4 | 26 | 4 | 27 | 3 | 27 | 3 |
| Cut-off | 16 | 14 | 14 | 16 | 14 | 16 | 14 | 16 | 15 | 15 | 13 | 17 | 14 | 16 | 16 | 14 | 16 | 14 |
| +25% Cut-off | 3 | 27 | 3 | 27 | 3 | 27 | 3 | 27 | 3 | 27 | 3 | 27 | 3 | 27 | 4 | 26 | 4 | 26 |
| +50% Cut-off | 0 | 30 | 0 | 30 | 0 | 30 | 0 | 30 | 0 | 30 | 0 | 30 | 0 | 30 | 0 | 30 | 0 | 30 |
| +300% Cut-off | 0 | 30 | 0 | 30 | 0 | 30 | 0 | 30 | 0 | 30 | 0 | 30 | 0 | 30 | 0 | 30 | 0 | 30 |

| Drug | TH | HC | TH | HC | TH | HC | M | TD | M | ΓD | M | ΓD | M | ΞT | M | ΕT | M | ΞT | M | EΤ |
|---------------|----|----|----|----|----|----|----|----|----|----|----|----|-----|-----|----|----|----|----|----|----|
| Concentration | 1 | 50 | 5 | 0 | 2 | 5 | 30 | 00 | 20 | 00 | 10 | 00 | 1,0 | 000 | 50 | 00 | 30 | 00 | 20 | 00 |
| Cut-off Range | - | + | - | + | - | + | - | + | - | + | - | + | - | + | - | + | - | + | - | + |
| 0% Cut-off | 30 | 0 | 30 | 0 | 30 | 0 | 30 | 0 | 30 | 0 | 30 | 0 | 30 | 0 | 30 | 0 | 30 | 0 | 30 | 0 |
| -50% Cut-off | 30 | 0 | 30 | 0 | 30 | 0 | 30 | 0 | 30 | 0 | 30 | 0 | 30 | 0 | 30 | 0 | 30 | 0 | 30 | 0 |
| -25% Cut-off | 27 | 3 | 26 | 4 | 27 | 3 | 27 | 3 | 27 | 3 | 27 | 3 | 27 | 3 | 27 | 3 | 27 | 3 | 27 | 3 |
| Cut-off | 15 | 15 | 14 | 16 | 15 | 15 | 13 | 17 | 15 | 15 | 14 | 16 | 16 | 14 | 15 | 15 | 16 | 14 | 15 | 15 |
| +25% Cut-off | 4 | 26 | 3 | 27 | 4 | 26 | 4 | 26 | 4 | 26 | 5 | 25 | 3 | 27 | 4 | 26 | 3 | 27 | 4 | 26 |
| +50% Cut-off | 0 | 30 | 0 | 30 | 0 | 30 | 0 | 30 | 0 | 30 | 0 | 30 | 0 | 30 | 0 | 30 | 0 | 30 | 0 | 30 |
| +300% Cut-off | 0 | 30 | 0 | 30 | 0 | 30 | 0 | 30 | 0 | 30 | 0 | 30 | 0 | 30 | 0 | 30 | 0 | 30 | 0 | 30 |

| Drug Concentration Cut-off Range | | MA 000 | | MA 00 | MC O 30 | PI | 0 | DP/ PI D0 | O 2,0 | PI 000 | P(| CP 0 | P(| CP 5 | | PX 00 |
|----------------------------------|----|-----------|----|----------|---------------|----|----|-----------------|----------|-----------|----|---------|----|---------|----|----------|
| | - | + | - | + | - | + | - | + | - | + | - | + | - | + | - | + |
| 0% Cut-off | 30 | 0 | 30 | 0 | 30 | 0 | 30 | 0 | 30 | 0 | 30 | 0 | 30 | 0 | 30 | 0 |
| -50% Cut-off | 30 | 0 | 30 | 0 | 30 | 0 | 30 | 0 | 30 | 0 | 30 | 0 | 30 | 0 | 30 | 0 |
| -25% Cut-off | 26 | 4 | 25 | 5 | 26 | 4 | 26 | 4 | 27 | 3 | 26 | 4 | 25 | 5 | 26 | 4 |
| Cut-off | 15 | 15 | 14 | 16 | 15 | 15 | 15 | 15 | 15 | 15 | 15 | 15 | 15 | 15 | 14 | 16 |
| +25% Cut-off | 5 | 25 | 4 | 26 | 3 | 27 | 3 | 27 | 5 | 25 | 3 | 27 | 3 | 27 | 3 | 27 |
| +50% Cut-off | 0 | 30 | 0 | 30 | 0 | 30 | 0 | 30 | 0 | 30 | 0 | 30 | 0 | 30 | 0 | 30 |
| +300% Cut-off | 0 | 30 | 0 | 30 | 0 | 30 | 0 | 30 | 0 | 30 | 0 | 30 | 0 | 30 | 0 | 30 |

| Drug | TN | ЛL | TN | ИL | TN | ЛL | TI | ML | KE | ΞT | KE | T | K | ΞT | K | ΞT | M | QL |
|---------------|----|----|----|----|----|----|----|----|-----|----|----|----|----|----|----|----|----|----|
| Concentration | 10 | 00 | 20 | 00 | 30 | 00 | 5 | 00 | 1,0 | 00 | 50 | 00 | 30 | 00 | 10 | 00 | 30 | 00 |
| Cut-off Range | - | + | - | + | - | + | | + | | + | | + | • | + | - | + | - | + |
| 0% Cut-off | 30 | 0 | 30 | 0 | 30 | 0 | 30 | 0 | 30 | 0 | 30 | 0 | 30 | 0 | 30 | 0 | 30 | 0 |
| -50% Cut-off | 30 | 0 | 30 | 0 | 30 | 0 | 30 | 0 | 30 | 0 | 30 | 0 | 30 | 0 | 30 | 0 | 30 | 0 |
| -25% Cut-off | 27 | 3 | 27 | 3 | 27 | 3 | 26 | 4 | 27 | 3 | 27 | 3 | 26 | 4 | 27 | 3 | 27 | 3 |
| Cut-off | 15 | 15 | 15 | 15 | 15 | 15 | 14 | 16 | 16 | 14 | 15 | 15 | 15 | 15 | 15 | 15 | 15 | 15 |
| +25% Cut-off | 4 | 26 | 4 | 26 | 4 | 26 | 3 | 27 | 3 | 27 | 4 | 26 | 4 | 26 | 3 | 27 | 4 | 26 |
| +50% Cut-off | 0 | 30 | 0 | 30 | 0 | 30 | 0 | 30 | 0 | 30 | 0 | 30 | 0 | 30 | 0 | 30 | 0 | 30 |
| +300% Cut-off | 0 | 30 | 0 | 30 | 0 | 30 | 0 | 30 | 0 | 30 | 0 | 30 | 0 | 30 | 0 | 30 | 0 | 30 |

| Drug Concentration | 0 | ΧY | 0 | ΧY | C | TC | C | TC | ED | DP | ED | DP | F١ | /L | F١ | /L |
|--------------------|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|
| Cut-off Range | 10 | 00 | 30 | 00 | 20 | 00 | 10 | 00 | 30 | 00 | 10 | 00 | 2 | 0 | 1 | 0 |
| Cut-on Kange | - | + | - | + | - | + | - | + | - | + | - | + | - | + | - | + |
| 0% Cut-off | 30 | 0 | 30 | 0 | 30 | 0 | 30 | 0 | 30 | 0 | 30 | 0 | 30 | 0 | 30 | 0 |
| -50% Cut-off | 30 | 0 | 30 | 0 | 30 | 0 | 30 | 0 | 30 | 0 | 30 | 0 | 30 | 0 | 30 | 0 |
| -25% Cut-off | 27 | 3 | 27 | 3 | 27 | 3 | 27 | 3 | 27 | 3 | 26 | 4 | 27 | 3 | 27 | 3 |

| Cut-off | | 15 | 15 | 5 1 | 5 | 15 | 15 | 15 | 14 | 16 | 3 1 | 5 | 15 | 15 | 15 | 1 | 4 | 16 | 15 | 1 |
|--|---|---|--|--|---|--|--|--|--|--|--|--|---|---|--|---|---|--|--|---|
| +25% Cut-o | ff | 4 | 26 | 3 . | 4 | 26 | 4 | 26 | 4 | 26 | 3 4 | 1 | 26 | 3 | 27 | . 4 | 1 | 26 | 3 | - |
| +50% Cut-o | ff | 0 | 30 |) (| 0 : | 30 | 0 | 30 | 0 | 30 |) (|) | 30 | 0 | 30 | (|) | 30 | 0 | |
| +300% Cut-0 | off | 0 | 30 |) (| 0 : | 30 | 0 | 30 | 0 | 30 |) (|) | 30 | 0 | 30 | (|) | 30 | 0 | |
| Drug | | K2 | | (2 | 6-1 | MAN | и м | DA | E | G | ET | G | ΕΊ | G | CL | Ω | С | LO | LS | 3 |
| Concentration | | 50 | | 30 | | 10 | | 00 | | 00 | 50 | | | 00 | _ | 00 | | 50 | | 20 |
| Cut-off Range | _ | T + | +-` | 1+ | ١. | + | 1- | 1+ | _ | + | - | + | - | + | - | + | - | 1+ | _ | Ì |
| 0% Cut-off | 30 | +- | 30 | _ | +- | +- | + | + | 30 | 0 | 30 | 0 | 30 | 0 | 30 | 0 | 30 | + | 30 | t |
| | _ | _ | _ | _ | _ | _ | _ | | 1 | | | | | | | | | _ | | ł |
| -50% Cut-off | 30 | _ | 30 | | +- | | 30 | +- | 30 | 0 | 30 | 0 | 30 | 0 | 30 | 0 | 30 | _ | 30 | ł |
| -25% Cut-off | 26 | _ | 27 | +- | 27 | +- | 26 | +- | 25 | 5 | 26 | 4 | 26 | 4 | 26 | 4 | 26 | _ | 27 | ł |
| Cut-off | 15 | _ | +- | +- | +- | +- | + | _ | 16 | 14 | 15 | 15 | 15 | 15 | 14 | 16 | 14 | _ | 14 | ļ |
| +25% Cut-off | 3 | _ | _ | 26 | +- | +- | + | 27 | 4 | 26 | 3 | 27 | 3 | 27 | 5 | 25 | 5 | 25 | 3 | Ŀ |
| +50% Cut-off | 0 | _ | +- | 30 | +- | 30 | + | 30 | 0 | 30 | 0 | 30 | 0 | 30 | 0 | 30 | 0 | 30 | 0 | į |
| +300% Cut-off | 0 | 30 | 0 | 30 | 0 | 30 | 0 | 30 | 0 | 30 | 0 | 30 | 0 | 30 | 0 | 30 | 0 | 30 | 0 | ŀ |
| | | | | | | | | | _ | | 1 | | 1 | | 1 | | _ | | _ | |
| Drug | L | SD | Z | OL | 2 | ZOL | М | DM/ | \ T | НС | | OP/ | М | ΕP | М | ΕP | М | DPV | E | Т |
| Concentration | | 50 | | 50 | | 25 | | 300 | 2 | 00 | | PI | 5 | 00 | 1 | 00 | 1. | ,000 | 1, | 5 |
| Cut-off Range | | | + | | + | | + | | +- | | 2 | 00 | | | | 1 | + | 1 | | 1 |
| | | + | +- | + | - | + | _ | + | - | + | - | + | - | + | - | + | - | + | - | 4 |
| 0% Cut-off | 30 | _ | + | _ | _ | _ | _ | _ | 30 | 0 | 30 | 0 | 30 | 0 | 30 | 0 | 30 | _ | 30 | + |
| -50% Cut-off | 30 | _ | 30 | _ | _ | _ | _ | _ | 30 | 0 | 30 | 0 | 30 | 0 | 30 | 0 | 30 | _ | 30 | + |
| -25% Cut-off | 27 | | 26 | _ | + | _ | _ | _ | 26 | 4 | 26 | 4 | 27 | 3 | 27 | 3 | 26 | _ | 27 | + |
| Cut-off | 14 | _ | _ | _ | _ | _ | _ | _ | _ | 15 | 15 | 15 | 15 | 15 | 17 | 13 | +- | +- | - | 1 |
| +25% Cut-off | 3 | + | +- | 25 | _ | + | _ | _ | + | 26 | 4 | 26 | 4 | 26 | 5 | 25 | +- | _ | ÷ | ļ |
| +50% Cut-off | 0 | 30 | 0 | 30 | 0 0 | 30 | 0 0 | 30 | 0 | 30 | 0 | 30 | 0 | 30 | 0 | 30 | 0 | 30 | 0 | 1 |
| +300% Cut-off | 0 | 30 | 0 | 30 | 0 0 | 30 | 0 0 | 30 | 0 | 30 | 0 | 30 | 0 | 30 | 0 | 30 | 0 | 30 | 0 | _ |
| | | | | | | . 1 | | | | | | | | | | _ | | | | _ |
| Drug | MD | | MDI | | DI | | DI. | | TH | | THO | | K2 | | ZO | | | OP | MC | |
| Concentration | 50 | 0 | 30 | 0 | 30 | 10 | 20 | 0 | 300 |) | 30 | _ | 25 | | 30 | 0 | - 5 | 0 | 50 | 0(|
| Cut-off Range | - | + | - | + | - | + | - | + | _ | + | -+ | + | _ | + | - | + | - | + | - | L |
| 0% Cut-off | 30 | _ | 30 | 0 | 30 | 0 | 30 | _ | _ | 0 3 | 30 | _ | _ | 0 | 30 | 0 | 30 | 0 | 30 | Ļ |
| -50% Cut-off | 30 | 0 | 30 | 0 | 30 | 0 | 29 | 1 | 30 | 0 I3 | | Λ I | 30 | 0 | 30 | Λ. | | | | |
| 250/ 0.4 6# | | _ | | | | | | _ | 30 | 0 . | 30 | 0 ; | 30 | v | 30 | 0 | 30 | 0 | 30 | L |
| -25% Cut-off | 25 | _ | 26 | 4 | 27 | 3 | 27 | 3 | _ | _ | _ | _ | _ | _ | 28 | 2 | 30 27 | 3 | 30 28 | L |
| Cut-off | _ | 5 | 26 | _ | 27 15 | 3 15 | 27 | _ | 26 | 4 2 | 26 | 4 2 | 25 | 5 | _ | - | _ | _ | - | ۰ |
| | 15 | 5 | 26 14 | _ | 15 | | 27 15 | _ | 26 15 <i>°</i> | 4 2 15 1 | 26 4 1 | 4 2 | 25 14 | 5 | 28 17 | 2 | 27 | 3 | 28 | ŀ |
| Cut-off | 15 3 | 5 15 | 26 14 3 | 16 | 15 | 15 | 27 15 3 | 15 | 26 15 ² | 4 2 15 1 26 | 26 4 4 2 | 4 2 | 25 14 3 | 5 16 | 28 17 3 | 2 | 27 17 | 3 13 | 28 17 | 1 |
| Cut-off +25% Cut-off +50% Cut-off | 15 3 0 | 5 15 27 | 26 14 3 | 16 27 | 15 3 | 15 27 | 27 15 3 1 | 15 27 | 26 15 4 2 | 4 2 15 1 26 30 | 26 4 1 4 2 0 3 | 4 2 16 2 26 30 | 25 14 3 0 | 5 16 27 | 28 17 3 0 | 2 13 27 | 27 17 4 | 3 13 26 | 28 17 3 | |
| Cut-off +25% Cut-off +50% Cut-off +300% Cut-off | 15 3 0 | 5 15 27 30 30 | 26 14 3 0 | 16 27 30 30 | 15 3 0 0 | 15 27 30 30 | 27 15 3 1 0 | 15 27 29 30 | 26 15 1 4 2 0 3 | 4 2 15 1 26 30 30 | 26 - 4 1 4 2 0 3 | 4 2 6 2 80 | 25 14 3 0 0 | 5 16 27 30 30 | 28 17 3 0 | 2 13 27 30 30 | 27 17 4 0 | 3 13 26 30 30 | 28 17 3 0 | |
| Cut-off +25% Cut-off +50% Cut-off +300% Cut-off Drug | 15 3 0 0 | 5 15 27 30 30 ACL | 26 14 3 0 0 | 16 27 30 30 -AC | 15 3 0 0 | 15 27 30 30 7-A | 27 15 3 1 0 | 15 27 29 30 | 26 15 4 2 0 3 | 4 2 15 1 26 30 30 | 26 - 4 1 4 2 0 3 0 3 | 4 2 6 26 30 | 25 14 3 0 0 CA | 5 16 27 30 30 | 28 17 3 0 0 | 2 13 27 30 30 | 27 17 4 0 | 3 13 26 30 30 | 28 17 3 0 0 | , |
| Cut-off +25% Cut-off +50% Cut-off +300% Cut-off Drug Concentration | 15 3 0 0 7-7 3 | 5 15 27 30 30 30 ACL 00 | 26 14 3 0 0 | 16 27 30 30 -AC 200 | 15 3 0 0 | 15 27 30 30 | 27 15 3 1 0 CL | 15 27 29 30 | 26 15 4 2 0 3 0 5 7 1 7 1 | 4 2 15 1 26 30 30 30 1 | 26 - 14 1 14 2 2 0 3 3 0 3 CAF | 4 2 6 26 80 80 | 25 14 3 0 0 0 CA | 5 16 27 30 30 | 28 17 3 0 0 TF 3 | 2 13 27 30 30 | 27 17 4 0 0 | 3 13 26 30 30 30 ALP | 28 17 3 0 | , |
| Cut-off +25% Cut-off +50% Cut-off +300% Cut-off Drug Concentration Cut-off Range | 15 3 0 0 7-7 3 | 5 15 27 30 30 30 ACL 00 | 26 14 3 0 0 | 16 27 30 30 -AC 200 | 15 3 0 0 | 15 27 30 30 7-A 10 | 27 15 3 1 0 CL 0 | 15 27 29 30 CF 5 | 26 15 1 2 2 3 3 3 3 3 3 3 3 | 4 2 15 1 26 30 30 30 1 | 26 - 14 14 20 3 3 0 3 3 CAF ,000 0 4 | 4 2 16 26 30 30 | 25 14 3 2 0 3 0 3 CA ⁻ 150 | 5 16 27 30 30 7) | 28 17 3 0 0 TF 35 | 2 13 27 30 30 80 50 + | 27 17 4 0 0 | 3 13 26 30 30 30 ALP 100 | 28 17 3 0 0 α-F 1,1 | ; |
| Cut-off +25% Cut-off +50% Cut-off +300% Cut-off Drug Concentration Cut-off Range 0% Cut-off | 15 3 0 0 7-7 3 - | 5 15 27 30 30 30 ACL 00 + | 26 14 3 0 0 - | 16 27 30 30 -AC 200 | 15 3 0 0 | 15 27 30 30 7-A 10 - | 27 15 3 1 0 CL 0 + | 15 27 29 30 CF 5 | 26 15 4 2 0 3 0 5 YL 00 + | 4 2 15 1 26 30 30 1 1 - 30 | 26 4 1 4 2 2 3 3 3 3 4 4 4 4 4 4 | 4 2 26 80 80 | 25 14 3 : 0 : 0 : 150 - | 5 16 27 30 30 7 7 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 | 28 17 3 0 0 TF 38 - | 2 13 27 30 30 30 RO 50 + | 27 17 4 0 0 | 3 13 26 30 30 30 ALP 100 + | 28 17 3 0 0 α-F 1,0 - | 0 |
| Cut-off +25% Cut-off +50% Cut-off +300% Cut-off Drug Concentration Cut-off Range 0% Cut-off -50% Cut-off | 15 3 0 0 7-7 3 - 30 30 | 5 15 27 30 30 30 4 CL 00 0 0 0 | 26 14 3 0 0 0 7 1 1 1 1 1 1 1 1 1 | 16 27 330 330 -AC 200 - | 15 3 0 0 L + | 15 27 30 30 7-A 10 - | 27 15 3 1 0 CL 0 + 0 | 15 27 29 30 CF 5 - 30 30 | 26 15 4 2 0 3 0 3 0 0 0 0 0 0 | 4 2 15 1 26 8 80 1 1 - 30 30 | 26 4 1 1 4 2 2 0 3 0 3 CAF 0000 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 | 4 2 6 80 80 80 80 80 80 80 80 80 80 80 80 80 | 25 14 3 1 1 1 1 1 1 1 1 1 | 5 16 227 330 330 T 0 0 0 0 | 28 17 3 0 0 0 TF 38 - 30 30 | 2 13 27 30 30 80 50 + 0 | 27 17 4 0 0 | 3 13 26 30 30 30 ALP 100 + 0 0 | 28 17 3 0 0 0 α-F1,1 - 30 30 | 5 0 |
| Cut-off +25% Cut-off +50% Cut-off +300% Cut-off Drug Concentration Cut-off Range 0% Cut-off -50% Cut-off | 7- <i>j</i> 3 0 0 7- <i>j</i> 3 - 30 30 26 | 5 15 27 30 30 30 4 4 0 0 4 | 26 14 3 0 0 0 1 1 1 1 1 1 1 | 16 27 30 30 30 -AC 200 - | 15 3 0 0 1 L | 15 27 30 30 7-A 10 - | 27 15 3 1 0 CL 0 + 0 0 3 | 15 27 29 30 CF 5 30 30 25 | 26 4 4 4 4 4 4 4 4 4 | 4 2 15 1 26 3 30 1 1 - 30 30 26 | 26 4 1 1 4 2 2 0 3 3 0 3 CAF 0000 4 4 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 | 4 2 16 26 80 80 30 2 | 25 14 3 3 0 3 15 0 3 15 0 | 5 16 27 330 330 T 0 0 3 | 28 17 3 0 0 0 TF 38 - 30 30 27 | 2 13 27 30 30 30 80 50 + 0 0 | 27 17 4 0 0 30 31 22 | 3 13 26 30 30 30 + 100 + 0 0 0 0 | 28 17 3 0 0 0 α-F 1,4 - 30 30 26 | 2 0 |
| Cut-off +25% Cut-off +50% Cut-off +300% Cut-off Drug Concentration Cut-off Range 0% Cut-off -50% Cut-off -25% Cut-off Cut-off | 15 3 0 0 7-7 3 - 30 30 26 14 | 5 15 27 30 30 30 4 4 16 | 26 14 3 0 0 14 3 0 0 14 15 15 15 15 15 15 15 | 16 27 30 30 30 -AC 200 - | 15 3 0 0 0 L + + + D) 3 6 | 15 27 30 30 30 7-A 10 - 30 30 30 31 31 31 | 27 15 3 1 0 0 CL 0 0 3 17 | 15 27 29 330 CF 5 - 30 30 25 14 | 26 4 2 4 2 4 2 4 2 4 2 4 2 4 4 | 4 2 15 1 26 80 80 1 1 - 30 30 26 17 | 26 4 1 1 4 2 2 2 2 2 2 2 2 2 | 4 2 16 26 80 80 2 2 3 3 1 | 25 14 3 1 3 3 | 5 16 27 330 330 Tr 0 0 3 13 | 28 17 3 0 0 TF 35 - 30 30 27 15 | 2 13 27 30 30 50 + 0 0 3 | 27 17 4 0 0 - 31 31 32 1 | 3 13 26 30 30 30 4LP ++00 0 0 0 0 0 0 8 2 7 13 | 28 17 3 0 0 0 α-F 1,1,1 - 30 30 26 31 5 | |
| Cut-off +25% Cut-off +50% Cut-off +300% Cut-off Drug Concentration Cut-off Range 0% Cut-off -50% Cut-off -25% Cut-off Cut-off +25% Cut-off | 15 3 0 0 7-3 30 30 30 26 14 5 | 5 15 27 30 30 30 4 16 25 | 26 114 3 0 0 0 0 0 0 0 0 0 | -AC-200 (1) (1) (2) (2) (2) (2) (3) (4) (4) (4) (4) (4) (4) (4) (4) (4) (4 | 15 3 0 0 0 C C C C C C C C C C C C C C C C | 15 27 30 30 30 7-A 10 - 330 330 27 13 4 | 27 15 3 1 0 CL 0 + 0 0 3 17 26 | 15 27 29 30 CF 5 - 30 25 14 6 | 26 15 4 2 2 3 3 3 3 3 3 3 3 | 4 2 15 1 16 80 80 1 1 - 30 30 26 17 6 | 26 4 1 1 1 2 2 4 2 2 4 2 2 2 2 | 4 2 16 26 80 80 3 2 2 3 3 1 1 | 25 14 3 2 3 3 3 3 3 3 3 3 | 5 5 16 16 17 17 17 17 17 17 | 28 17 3 0 0 0 TF 38 - 30 30 27 15 3 | 2 13 27 30 30 50 + 0 0 3 15 27 | 27 17 4 0 0 30 30 20 11 30 | 3 13 26 30 30 30 ALP 100 + + 00 0 0 0 0 0 3 3 3 3 3 3 3 3 3 3 | 28 17 3 0 0 0 0 α-F 1,γ - 30 30 26 315 7 | 5 0 |
| Cut-off +25% Cut-off +50% Cut-off +300% Cut-off Drug Concentration Cut-off Range 0% Cut-off -50% Cut-off -25% Cut-off +25% Cut-off +50% Cut-off | 15 3 0 0 7-4 30 30 26 14 5 0 | 5 15 27 30 30 4 16 25 30 | 26 114 3 0 0 0 0 0 0 0 0 0 | -AC 2200 (1) (1) (1) (2) (2) (3) (4) (4) (4) (4) (4) (4) (4) (4) (4) (4 | 15 3 0 0 0 L L + + + + + + + + + + + + + + + | 15 27 30 30 30 7-A 10 - 30 30 30 27 113 4 | 27 15 3 1 0 CL 0 - 0 3 17 26 30 | 15 27 29 30 5 30 25 14 6 0 | 26 15 4 2 2 3 3 3 3 3 3 3 3 | 4 2 15 1 26 8 80 1 - 30 30 30 26 17 6 0 | 26 4 1 1 1 1 1 1 1 1 1 | 4 2 16 26 80 80 3 3 3 1 4 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 | 25 14 3 3 6 6 6 6 6 6 6 6 | 5 5 6 6 6 6 6 6 6 6 | 28 17 3 0 0 0 TF 38 - 30 27 15 3 0 | 2 13 27 30 30 50 + 0 0 3 15 27 30 | 27 17 4 0 0 33 36 26 11 30 0 | 3 13 26 30 30 30 4 4 100 0 0 0 0 0 0 3 3 3 0 3 0 3 0 0 0 0 0 | 28 17 3 0 0 0 -1,1,1 -30 30 30 26 315 7 3 0 0 | 2 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 |
| Cut-off +25% Cut-off +50% Cut-off +300% Cut-off Drug Concentration Cut-off Range 0% Cut-off -50% Cut-off -25% Cut-off +25% Cut-off +50% Cut-off | 15 3 0 0 7-3 30 30 30 26 14 5 | 5 15 27 30 30 30 4 16 25 | 26 114 3 0 0 0 0 0 0 0 0 0 | -AC 2200 (1) (1) (1) (2) (2) (3) (4) (4) (4) (4) (4) (4) (4) (4) (4) (4 | 15 3 0 0 0 C C C C C C C C C C C C C C C C | 15 27 30 30 30 7-A 10 - 330 330 27 13 4 | 27 15 3 1 0 CL 0 + 0 0 3 17 26 | 15 27 29 30 CF 5 - 30 25 14 6 | 26 15 4 2 2 3 3 3 3 3 3 3 3 | 4 2 15 1 16 80 80 1 1 - 30 30 26 17 6 | 26 4 1 1 1 2 2 4 2 2 4 2 2 2 2 | 4 2 16 26 80 80 3 3 3 1 4 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 | 25 14 3 3 7 150 17 17 17 17 17 17 17 1 | 5 5 16 16 17 17 17 17 17 17 | 28 17 3 0 0 0 TF 38 - 30 30 27 15 3 | 2 13 27 30 30 50 + 0 0 3 15 27 | 27 17 4 0 0 31 31 31 11 31 0 | 3 13 26 30 30 30 4 4 100 0 0 0 0 0 0 3 3 2 7 13 3 0 3 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 | 28 17 3 0 0 0 -1,1,1 -30 30 30 26 315 7 3 0 0 | 2 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 |
| Cut-off +25% Cut-off +50% Cut-off +300% Cut-off Drug Concentration Cut-off Range 0% Cut-off -50% Cut-off Cut-off +25% Cut-off +25% Cut-off +300% Cut-off | 7- <i>y</i> -30 3 30 30 30 26 14 5 0 | 5 15 27 30 30 30 4 16 25 30 30 | 26 14 3 0 0 0 0 0 0 0 0 0 | 16 27 330 33 | 15 3 0 0 0 L + + + + 7 0 0 0 0 | 15 27 30 30 30 7-A 10 - 330 330 34 0 0 0 | 27 15 3 1 0 CL 0 + 0 0 3 17 26 30 30 | 15 27 29 30 CF 5 30 30 25 14 6 0 0 | 26 15 4 4 2 0 3 0 3 0 16 16 16 16 16 16 16 | 4 2 15 1 126 830 830 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 | 26 4 1 1 1 1 1 1 1 1 1 | 4 2 2 6 80 80 80 3 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 | 25 14 3 2 3 3 3 3 3 3 3 3 | 5 16 27 330 330 13 13 226 330 | 28 17 3 0 0 0 TF 38 3 0 27 15 3 0 0 | 2 13 27 30 30 50 + 0 0 3 15 27 30 30 | 27 17 4 0 0 31 31 32 11 33 10 0 | 3 13 26 30 30 30 4LP +00 0 0 0 0 0 0 30 3 27 13 3 27 0 30 | 28 17 3 0 0 0 α-F 1,γ - 30 30 26 3 15 7 3 0 0 | 000 |
| Cut-off +25% Cut-off +50% Cut-off +300% Cut-off Drug Concentration Cut-off Range 0% Cut-off -50% Cut-off -25% Cut-off Cut-off +25% Cut-off +25% Cut-off +300% Cut-off Drug | 7-/ 3 0 0 0 7-/ 3 - 30 30 26 14 5 0 0 | 5 15 27 30 30 30 4 6 25 30 30 YL | 26 14 3 0 0 7 3 3 3 0 0 0 CC | 16 27 30 30 30 30 30 30 30 3 | 15 3 0 0 0 0 C C C C C C C C C C C C C C C | 15 27 30 30 7-A 10 - 330 30 4 0 0 CA | 27 15 3 1 0 17 17 26 30 30 TC | 15 27 29 30 5 5 5 6 0 0 CA | 26 15 4 2 0 3 0 5 16 24 30 30 TC | 4 2 15 1 1 2 2 6 8 8 0 8 0 1 1 - 3 3 0 2 6 1 7 6 6 0 0 0 0 | 26 4 1 4 2 2 4 1 1 1 2 2 4 3 3 3 6 6 6 6 6 6 6 | 4 2 2 6 80 80 80 3 3 1 4 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 | 25 14 3 2 14 3 2 15 15 15 15 15 15 15 | 5 16 27 330 330 13 226 330 330 C | 28 17 3 0 0 0 TF 30 30 27 15 3 0 0 CA | 2 13 27 30 30 50 + 0 0 3 15 27 30 30 | 27 17 4 0 0 3 3 3 2 1 1 0 0 0 | 3 13 26 30 30 30 4LP ++00 0 0 0 0 0 0 3 27 13 3 27 13 3 27 13 3 27 13 3 27 13 3 27 13 4 27 14 15 16 17 17 18 18 18 18 18 18 18 18 18 18 18 18 18 | 28 17 3 0 0 0 α-F 1,1 - 30 30 26 315 7 3 0 0 0 0 | D'O |
| Cut-off +25% Cut-off +50% Cut-off +300% Cut-off Drug Concentration Cut-off Range 0% Cut-off -50% Cut-off -25% Cut-off Cut-off +25% Cut-off +50% Cut-off +300% Cut-off Drug Concentration | 7-/ 3 0 0 0 7-/ 3 - 30 30 26 14 5 0 0 | 5 15 27 30 30 30 4 16 25 30 30 30 YL 00 00 00 00 00 00 0 | 26 14 3 0 0 7 3 3 3 0 0 0 CC | -AC 2000 | 15 3 0 0 0 0 C C C C C C C C C C C C C C C | 15 27 30 30 30 | 27 15 3 1 0 17 17 26 30 30 TC | 15 27 29 30 5 5 5 5 6 6 6 6 6 6 | 26 15 4 4 2 0 3 0 3 0 16 16 16 16 16 16 16 | 4 2 2 15 1 1 2 6 3 3 0 3 0 2 6 4 0 0 0 A 0 0 | 26 4 1 1 1 1 1 1 1 1 1 | 4 2 2 6 8 8 0 8 0 8 0 0 0 0 0 0 0 0 0 0 0 0 0 | 25 14 3 2 3 3 3 3 3 3 3 3 | 5 16 27 330 330 T 0 3 3 3 3 3 3 3 C C 0 0 0 0 0 0 0 0 | 28 17 3 0 0 | 2 13 27 30 30 50 + + 0 3 15 27 30 30 30 | 27 17 4 0 0 31 31 31 21 1 0 0 0 | 3 13 26 30 30 30 30 4LP 1100 + + 00 0 0 3 3 27 13 3 27 13 3 3 3 4 4 4 4 4 4 5 6 7 1 3 6 7 1 3 6 7 1 3 6 7 1 3 7 1 3 7 1 3 7 1 3 7 1 3 1 3 7 1 7 1 | 28 17 3 0 0 0 α-F 1,γ - 30 30 26 3 15 7 3 0 0 |) O O |
| Cut-off +25% Cut-off +50% Cut-off +300% Cut-off Drug Concentration Cut-off Range 0% Cut-off -50% Cut-off Cut-off +25% Cut-off +25% Cut-off +50% Cut-off +300% Cut-off Drug Concentration Cut-off Range | 7-/3 0 0 0 0 30 30 26 14 5 0 0 | 5 15 27 30 30 30 4 16 25 30 30 4 16 25 30 30 4 16 16 16 16 16 16 16 | 26 14 3 0 0 7 | -AC 2000 (3) (4) (4) (5) (7) (7) (7) (7) (7) (7) (7) (7) (7) (7 | 15 3 0 0 0 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 | 15 27 30 30 30 7-A 10 - 30 30 30 4 0 0 0 CA 0000 + + | 27 15 3 1 0 0 17 17 17 17 17 | 15 27 29 30 5 5 5 6 6 0 14 6 0 14 15 15 15 15 15 15 15 | 26 15 4 2 15 16 16 16 16 16 16 16 | 4 2 15 11 26 80 80 11 - 30 30 26 17 6 0 0 + 1 | 26 4 1 4 2 2 4 1 1 3 3 3 3 5 5 5 5 5 5 | 4 2 6 80 80 33 1 4 90 90 1 90 1 90 1 90 1 90 1 90 1 90 1 9 | 25 14 3 2 3 3 3 3 3 3 3 3 | 5 16 27 330 330 T 0 3 330 330 C C C C C C C C C | 28 17 3 0 0 15 3 0 0 15 3 0 0 CA 2,0 - 1 1 1 1 1 1 1 1 1 | 2 13 27 30 30 50 + 0 0 3 15 27 30 30 4 8 00 + | 27 17 4 0 0 31 31 31 21 1 1 0 0 | 3 13 26 30 30 30 ALP + + 00 00 0 0 0 0 30 30 30 4 4 7 13 3 27 13 3 3 3 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 | 28 17 3 0 0 0 1, 3 30 30 30 26 3 15 7 3 3 0 0 0 0 C / 5 5 5 5 5 5 5 5 5 5 | D'OIT A |
| Cut-off +25% Cut-off +50% Cut-off +300% Cut-off Drug Concentration Cut-off Range 0% Cut-off -50% Cut-off -25% Cut-off Cut-off +25% Cut-off +50% Cut-off +300% Cut-off Drug Concentration | 7-/ 3 0 0 0 7-/ 3 - 30 30 26 14 5 0 0 | 5 15 27 30 30 30 4 16 25 30 30 30 YL 00 00 00 00 00 00 0 | 26 14 3 0 0 7 3 3 3 0 0 0 CC | -AC 2000 | 15 3 0 0 0 0 C C C C C C C C C C C C C C C | 15 27 30 30 30 7-A 10 - 30 30 30 4 0 0 0 CA 0000 + + | 27 15 3 1 0 17 17 26 30 30 TC | 15 27 29 30 5 5 5 5 6 6 6 6 6 6 | 26 15 4 2 0 3 0 5 16 24 30 30 TC | 4 2 15 11 26 80 80 11 - 30 30 26 17 6 0 0 + 1 | 26 4 1 4 2 2 4 1 1 1 2 2 4 3 3 3 6 6 6 6 6 6 6 | 4 2 2 6 8 8 0 8 0 8 0 0 0 0 0 0 0 0 0 0 0 0 0 | 25 14 3 2 3 3 3 3 3 3 3 3 | 5 16 27 330 330 T 0 3 3 3 3 3 3 3 C C 0 0 0 0 0 0 0 0 | 28 17 3 0 0 | 2 13 27 30 30 50 + + 0 3 15 27 30 30 30 | 27 17 4 0 0 3 3 3 2 1 1 0 0 0 0 0 | 3 13 26 30 30 30 4LP + 00 0 0 0 0 0 0 0 30 27 13 3 27 0 30 0 30 0 30 0 30 0 30 0 30 0 30 0 3 | 28 17 3 0 0 0 α-F 1,1 - 30 30 26 315 7 3 0 0 0 0 | D'OIT A |
| Cut-off +25% Cut-off +50% Cut-off +300% Cut-off Drug Concentration Cut-off Range 0% Cut-off -50% Cut-off Cut-off +25% Cut-off +25% Cut-off +50% Cut-off +300% Cut-off Drug Concentration Cut-off Range | 7-/3 0 0 0 0 30 30 26 14 5 0 0 | 5 15 27 30 30 30 4 16 25 30 30 4 16 25 30 30 4 16 16 16 16 16 16 16 | 26 14 3 0 0 7 | -AC 2000 (3) (4) (4) (5) (7) (7) (7) (7) (7) (7) (7) (7) (7) (7 | 15 3 0 0 0 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 | 7-A 10 - 30 330 330 330 27 113 4 0 0 0 | 27 15 3 1 0 0 17 17 17 17 17 | 15 27 29 30 5 5 5 6 6 0 14 6 0 14 15 15 15 15 15 15 15 | 26 15 4 2 15 16 16 16 16 16 16 16 | 4 2 15 1 1 26 | 26 4 1 4 2 2 4 1 1 3 3 3 3 5 5 5 5 5 5 | 4 2 6 80 80 33 1 4 90 90 1 90 1 90 1 90 1 90 1 90 1 90 1 9 | 25 14 3 2 3 3 3 3 3 3 3 3 | 5 16 27 330 330 T 0 3 330 330 C C C C C C C C C | 28 17 3 0 0 0 TF 33 30 27 15 3 0 0 CA 2,0 - | 2 13 27 30 30 50 + 0 0 3 15 27 30 30 4 8 00 + | 27 17 4 0 0 31 31 20 1 1 1 0 0 | 3 13 26 30 30 30 4LP + 00 0 0 0 0 0 0 0 30 27 13 3 27 0 30 0 30 0 30 0 30 0 30 0 30 0 30 0 3 | 28 17 3 0 0 0 C 5 5 5 5 5 5 5 5 | 0 A |
| Cut-off +25% Cut-off +50% Cut-off +300% Cut-off Drug Concentration Cut-off Range 0% Cut-off -50% Cut-off -25% Cut-off +25% Cut-off +50% Cut-off +300% Cut-off Drug Concentration Cut-off Range 0% Cut-off Cut-off Range | 7-/3 3 0 0 0 0 30 30 26 14 5 0 0 | 5 15 27 30 30 30 4 16 25 30 30 YL 00 + 0 0 16 16 16 16 16 16 | 26 14 3 0 0 0 0 0 0 0 0 0 | 16 27 30 30 30 30 30 30 30 3 | 15 3 0 0 0 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 | 7-A 10 - 30 30 30 7-A 10 - 30 30 30 CA 000 + 0 0 | 27 15 3 1 0 0 26 30 30 30 30 | 15 27 29 30 5 5 5 5 6 6 6 6 6 6 | 26 15 4 2 15 16 16 16 16 16 16 16 | 4 2 15 1 1 26 30 30 30 30 26 17 6 0 0 0 0 0 | 26 4 1 4 2 2 4 1 1 3 3 3 3 3 3 3 3 | 4 2 2 6 80 80 80 80 80 80 80 80 80 80 80 80 80 | 25 14 3 2 3 3 3 3 3 3 3 3 | 5 16 27 30 330 13 226 330 330 C C 0 + 0 | 28 17 3 0 0 0 TF 38 30 27 15 3 0 0 CA 2,0 - 30 30 | 2 13 27 30 30 50 50 15 27 30 30 30 4 R 00 + 0 | 27 17 4 0 0 3 3 3 2 1 1 0 0 0 0 0 | 3 13 26 30 30 30 4LP 100 0 0 0 0 0 3 3 2 7 13 3 2 7 13 3 3 2 7 13 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 | 28 17 3 0 0 0 30 30 26 3 15 7 3 0 0 0 | P) 00 A |
| Cut-off +25% Cut-off +50% Cut-off +300% Cut-off +300% Cut-off Drug Concentration Cut-off Range 0% Cut-off -50% Cut-off +25% Cut-off +50% Cut-off +300% Cut-off Drug Concentration Cut-off Range 0% Cut-off -50% Cut-off -50% Cut-off | 15 3 0 0 0 30 30 26 14 5 0 0 0 F 10 - 30 30 30 30 30 30 | 5 15 27 30 30 30 4 16 25 30 30 YL 00 + 0 0 0 0 0 0 0 | 26 14 3 0 0 0 0 0 0 0 0 0 | 16 27 30 30 30 30 30 30 30 3 | 15 3 0 0 0 0 L L | 7-A 10 - 330 330 7-A 10 - 1330 330 30 227 13 4 0 0 CA 0000 + 0 0 5 | 27 15 3 1 0 0 CL 0 3 17 26 30 30 30 26 | 15 27 29 30 5 30 25 14 6 0 0 CA 00 0 0 0 | 26 15 4 2 15 16 16 16 16 16 16 16 | 4 2 15 1 1 26 30 30 30 30 26 17 6 0 0 0 0 0 | 26 4 1 4 2 2 4 1 4 2 4 2 4 1 4 2 4 4 2 4 4 4 2 4 4 | 4 2 2 6 80 80 80 80 80 80 80 80 80 80 80 80 80 | 25 14 3 3 3 3 3 3 3 3 3 | 5 16 27 30 330 T 0 3 13 26 330 30 C 0 0 0 0 0 0 0 0 | 28 17 3 0 0 0 TF 33 30 27 15 3 0 0 CA 2,0 - 30 30 30 30 30 30 | 2 13 27 30 30 50 50 15 27 30 30 15 27 30 30 0 0 0 | 27 17 4 0 0 3 3 3 2 1 1 0 0 C 1, 3 3 3 3 3 3 3 3 3 3 3 3 3 | 3 13 26 30 30 30 4LP + + 0 0 0 0 3 3 3 3 2 7 13 3 2 7 13 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 | 28 17 3 0 0 0 | A 00 |
| Cut-off +25% Cut-off +50% Cut-off +300% Cut-off +300% Cut-off Cut-off Range 0% Cut-off -25% Cut-off +25% Cut-off +300% Cut-off +300% Cut-off Drug Concentration Cut-off Range 0% Cut-off -50% Cut-off -50% Cut-off -50% Cut-off -50% Cut-off | 7-/3 30 30 30 26 14 5 0 0 | 5 15 27 30 30 30 4 16 25 30 30 YL 00 0 0 3 30 30 30 30 | 26 14 3 0 0 14 3 0 0 15 15 15 15 15 15 | -AC 2000 (C) | 15 3 0 0 0 0 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 | 7-A 10 - 330 330 7-A 10 - 1330 330 30 227 13 4 0 0 CA 0000 + 0 0 5 | 27 15 3 1 0 0 1 1 1 1 1 1 1 | 15 27 29 30 30 25 14 6 0 0 CA 00 4 | 26 15 16 16 17 17 17 17 17 17 | 4 2 15 1 1 26 30 30 30 30 30 30 30 30 30 30 30 30 30 | 26 4 1 1 1 1 1 1 1 1 1 | 4 2 2 2 3 3 1 4 5 5 5 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 | 25 14 3 3 3 3 3 3 3 3 3 | 5 16 27 330 330 T 0 3 3 13 26 330 C 0 1 4 0 0 4 4 | 28 17 3 0 0 0 TF 38 30 27 15 3 0 0 0 CA 2,0 30 30 28 | 2 13 27 30 30 50 50 15 27 30 30 30 4 00 4 0 0 | 27 17 4 0 0 3 3 3 2 1 1 1 1 2 1 3 0 0 0 0 | 3 13 26 30 30 30 4LP + + 0 0 0 0 3 3 3 3 2 7 13 3 2 7 13 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 | 28 17 3 0 0 0 -1,1,1 -30 30 26 3 15 7 3 0 0 0 0 0 0 27 | AI (1) |
| Cut-off +25% Cut-off +25% Cut-off +50% Cut-off +300% Cut-off Drug Concentration Cut-off Range 0% Cut-off -50% Cut-off Cut-off +25% Cut-off +300% Cut-off +300% Cut-off Drug Concentration Cut-off Range 0% Cut-off -50% Cut-off -50% Cut-off -50% Cut-off -55% Cut-off -25% Cut-off -25% Cut-off | 7-/-3 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 | 115 27 30 30 30 4 6 25 30 30 YL 00 0 3 15 | 26 14 3 0 0 0 0 0 0 0 0 0 | 16 27 30 30 30 -AC 2000 - | 15 3 0 0 0 C C C C C C C C C C C C C C C C | 7-A 10 - 330 330 330 330 - 10 - 10 - 10 - 1 | 27 15 3 1 0 0 3 17 26 30 30 26 14 3 | 15 27 29 30 30 30 25 14 6 0 0 CA 00 4 16 | 26 115 1 | 4 2 15 1 1 26 30 30 30 30 30 30 4 6 0 4 1 0 0 3 1 1 6 | 26 4 1 4 2 2 2 3 3 3 3 3 3 3 | 4 2 2 2 3 3 1 4 2 0 0 0 0 3 1 1 6 1 6 1 6 1 6 1 6 1 6 1 6 1 6 1 6 | 25 14 3 3 3 3 3 3 3 3 3 | 5 16 27 330 330 Tr 0 3 313 226 330 30 Cr 0 4 16 | 28 117 3 0 0 0 TF 38 30 27 15 3 0 0 0 CA 2,0 0 30 28 116 | 2 13 27 30 30 50 50 15 27 30 30 15 27 30 30 15 27 30 30 15 27 30 30 15 27 30 30 30 30 30 40 40 40 40 40 40 40 40 40 40 40 40 40 | 27 17 4 0 0 30 30 30 27 16 | 3 13 26 30 30 30 4LP + + 0 0 0 0 3 3 27 13 27 13 3 27 13 3 27 13 3 4 14 | 28 17 3 0 0 0 30 26 3 15 7 3 0 0 0 0 0 26 15 7 3 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 | AI |

| Drug | M | PD | 1 | MPE |) | M | PD | F | PGE | 3 | P | ЗB | G | AB | | TZI |) | (1) | ΝB | PA | ٩P |
|--|--|--|---|---|---|--|---|---|--|---|---|--|---|--|---|---|---|--|---|---|--|
| Concentration | 1 | 50 | | 300 |) | 1,0 | 000 | 50 | 0,00 | 00 | 5 | 00 | 2 | 000 | | 200 |) | 50 | 00 | 50 | 00 |
| Cut-off Range | - | + | - | - 1 | + | - | + | - | 1 - | + | - | + | - | + | | - | + | - | + | - | + |
| 0% Cut-off | 30 | 0 | 30 |) (| 0 ; | 30 | 0 | 30 |) (| 0 | 30 | 0 | 30 | 0 | 3 | 0 | 0 | 30 | 0 | 30 | 0 |
| -50% Cut-off | 30 | 0 | 30 |) (| 0 ; | 30 | 0 | 30 |) (| 0 | 30 | 0 | 30 | 0 | 3 | 0 | 0 | 30 | 0 | 30 | 0 |
| -25% Cut-off | 26 | 4 | 27 | 7 : | 3 : | 26 | 4 | 25 | 5 5 | 5 | 25 | 5 | 28 | 2 | 2 | 8 | 2 | 27 | 3 | 29 | 1 |
| Cut-off | 15 | 15 | 16 | 3 1 | 4 | 16 | 14 | 15 | 5 1 | 5 | 15 | 15 | 14 | 16 | 3 1 | 4 | 16 | 14 | 16 | 15 | 15 |
| +25% Cut-off | 5 | 25 | 5 | 2 | 25 | 5 | 25 | 5 | 2 | 25 | 6 | 24 | 3 | 27 | , ; | 3 : | 27 | 4 | 26 | 1 | 29 |
| +50% Cut-off | 0 | 30 | 0 | 3 | 30 | 0 | 30 | 0 | 3 | 30 | 0 | 30 | 0 | 30 |) (|) ; | 30 | 0 | 30 | 0 | 30 |
| +300% Cut-off | 0 | 30 | 0 | 3 | 30 | 0 | 30 | 0 | 3 | 30 | 0 | 30 | 0 | 30 |) (|) ; | 30 | 0 | 30 | 0 | 30 |
| | | | | | | | | | _ | | | | | | | | | | | | |
| Drug | ΑB | | QT | ъ | FI | LX | l k | (RA | | TLI | пΙ | α-P | VΡ | α-P | VP | α-F | VP | L | SD | н | ИΟ |
| Concentration | K | | 1,0 | | | 00 | | 300 | | 50 | | 2,0 | | 50 | | | 00 | | 10 | 1 | 00 |
| Cut-off Range | 10 |) | | | | | <u> </u> | | 4 | | | -,- | | | _ | _ | _ | <u> </u> | _ | Ĭ | |
| Ů | - | + | - | + | - | + | - | + | + | - | + | - | + | - | + | - | + | - | + | - | + |
| | 30 | _ | 30 | 0 | 30 | 0 | 30 | +- | ÷ | 0 | 0 | 30 | 0 | 30 | 0 | 30 | 0 | 30 | 0 | 30 | 0 |
| | 30 | _ | 30 | 0 | 30 | 0 | 30 | _ | - | 0 | 0 | 30 | 0 | 30 | 0 | 30 | 0 | 30 | 0 | 30 | 0 |
| | 25 | _ | 29 | 1 | 29 | 1 | 28 | _ | _ | 9 | 1 | 26 | 4 | 27 | 3 | 27 | 3 | 27 | 3 | 28 | 2 |
| | 15 | _ | 15 | 15 | 15 | 15 | _ | _ | _ | _ | 15 | 15 | 15 | | 15 | 15 | 15 | 14 | 16 | 15 | 15 |
| +25% Cut-off | 4 | 26 | 1 | 29 | 2 | 28 | _ | 29 | _ | _ | 29 | 3 | 27 | | 27 | 3 | 27 | 3 | 27 | 3 | 27 |
| +50% Cut-off | 0 | 30 | 0 | 30 | 0 | 30 | _ | 30 | _ | _ | 30 | _ | 30 | _ | 30 | 0 | 30 | 0 | 30 | 0 | 30 |
| +300% Cut-off | 0 | 30 | 0 | 30 | 0 | 30 | 0 | 30 |) (| 0 ; | 30 | 0 | 30 | 0 | 30 | 0 | 30 | 0 | 30 | 0 | 30 |
| | | | | | | | | | | | | _ | | | | | | | | | |
| Drug Co | тс | CC | т | CC | т | CF | YL | F١ | /L | z | AL | MF | PRD | T | AΡ | С | IT | FK | ΈT | UR- | |
| - | | _ | | | | | | | | | | | | | | | | | | K | |
| Concentration 50 | 00 | 5 | 0 | 1 | 0 | 25 | 50 | 20 | 00 | 1 | 00 | 1 | 00 | 1,0 | 000 | 5 | 00 | 1,0 | 000 | | |
| Cut-off Range | _ | | _ | | | | | | | <u> </u> | | <u> </u> | | | | | _ | Ľ | | 2 | 5 |
| Cut-off Range | + | - | + | - | + | - | + | - | + | - | + | - | + | - | + | - | + | - | + | - | 5 + |
| Cut-off Range - 0% Cut-off 30 | + | - 30 | + | - 30 | + | - 30 | + | - 30 | + | - 30 | + | 30 | + | - 30 | + | 30 | + | - 30 | + | - 30 | 5 + 0 |
| Cut-off Range - 0% Cut-off 30 -50% Cut-off 30 | + 0 0 | - 30 30 | + 0 | - 30 30 | + 0 0 | - 30 30 | + 0 0 | - 30 30 | + 0 0 | 30 | + 0 0 | 30 | 0 | 30 | 0 | - 30 30 | 0 | 30 | + 0 0 | - 30 30 | 5 + 0 |
| Cut-off Range - 0% Cut-off 30 -50% Cut-off 30 -25% Cut-off 26 | + 0 0 4 | - 30 30 27 | + 0 0 3 | - 30 30 27 | + 0 0 3 | 30 30 25 | + 0 0 5 | - 30 30 27 | + 0 0 | 30 30 27 | + 0 0 0 | 30 30 27 | + 0 0 | - 30 30 27 | + 0 0 | 30 30 27 | + 0 0 | - 30 30 27 | + 0 0 | - 30 30 28 | 5 + 0 0 |
| Cut-off Range - 0% Cut-off 30 -50% Cut-off 30 -25% Cut-off 26 Cut-off 14 | + 0 0 4 16 | - 30 30 27 16 | + 0 0 3 14 | - 30 30 27 15 | + 0 0 3 15 | 30 30 25 | + 0 0 5 | - 30 30 27 15 | + 0 0 3 15 | 30 30 27 15 | + 0 0 0 0 7 3 5 15 | 30 30 27 5 15 | + 0 0 3 | - 30 30 27 15 | + 0 0 3 15 | - 30 30 27 15 | + 0 0 3 15 | - 30 30 27 15 | + 0 0 3 15 | - 30 30 28 15 | 5 0 0 2 |
| Cut-off Range - 0% Cut-off 30 -50% Cut-off 30 -25% Cut-off 26 Cut-off 14 +25% Cut-off 3 | + 0 0 4 16 27 | - 30 30 27 16 4 | + 0 0 3 14 26 | - 30 30 27 15 | + 0 0 3 15 26 | - 30 30 25 14 | + 0 0 5 16 24 | - 30 30 27 15 3 | + 0 0 3 15 27 | - 30 30 27 15 | + 0 0 0 0 7 3 5 15 26 | 30 30 27 5 15 6 2 | + 0 0 3 15 28 | - 30 30 27 15 4 | + 0 0 3 15 | - 30 30 27 15 4 | + 0 0 3 15 26 | - 30 30 27 15 3 | + 0 0 3 15 27 | - 30 30 28 15 3 | 5 + 0 0 2 15 |
| Cut-off Range - 0% Cut-off 30 -50% Cut-off 26 -25% Cut-off 14 +25% Cut-off 3 +50% Cut-off 0 | + 0 0 4 16 | - 30 30 27 16 | + 0 0 3 14 | - 30 30 27 15 | + 0 0 3 15 | 30 30 25 | + 0 0 5 | - 30 30 27 15 | + 0 0 3 15 | 30 30 27 15 | + 0 0 0 0 7 3 5 15 | 30 30 27 5 15 6 2 | + 0 0 3 | - 30 30 27 15 4 | + 0 0 3 15 | - 30 30 27 15 | + 0 0 3 15 | - 30 30 27 15 | + 0 0 3 15 | - 30 30 28 15 | 5 + 0 0 2 15 |
| Cut-off Range - 0% Cut-off 30 -50% Cut-off 30 -25% Cut-off 26 Cut-off 14 +25% Cut-off 3 +50% Cut-off 0 +300% 0 | + 0 0 4 16 27 | - 30 30 27 16 4 | + 0 0 3 14 26 | - 30 30 27 15 | + 0 0 3 15 26 | - 30 30 25 14 | + 0 0 5 16 24 | - 30 30 27 15 3 | + 0 0 3 15 27 | - 30 30 27 15 | + 0 0 0 0 7 3 5 15 26 | 30 30 27 5 15 6 2 0 0 | + 0 0 3 15 28 | - 30 30 27 15 4 | + 0 0 3 15 | - 30 30 27 15 4 | + 0 0 3 15 26 | - 30 30 27 15 3 | + 0 0 3 15 27 | - 30 30 28 15 3 | 5 + 0 2 15 27 30 |
| Cut-off Range - 0% Cut-off 30 -50% Cut-off 26 -25% Cut-off 26 -25% Cut-off 4 +25% Cut-off 3 +300% | + 0 0 4 16 27 30 | - 30 30 27 16 4 0 | + 0 0 3 14 26 30 | - 30 30 27 15 4 0 | + 0 0 3 15 26 30 | - 30 30 25 14 6 | + 0 0 5 16 24 30 | - 30 30 27 15 3 | + 0 0 3 15 27 30 | - 30 30 27 15 4 | + 0 0 0 0 7 3 5 15 26 30 | 30 30 27 5 15 6 2 0 0 | + 0 0 3 15 28 30 | - 30 30 27 15 4 | + 0 0 3 15 26 30 | - 30 30 27 15 4 | + 0 0 3 15 26 30 | - 30 30 27 15 3 | + 0 0 3 15 27 | 2 30 30 28 15 3 | 5 + 0 0 2 15 27 30 |
| Cut-off Range | + 0 0 4 16 27 30 | - 30 30 27 16 4 0 | + 0 0 0 3 14 26 30 30 | - 30 30 27 15 4 0 | + 0 0 3 15 26 30 30 | 30 30 25 14 6 0 | + 0 0 5 16 24 30 | - 30 30 27 15 3 0 | + 0 0 3 15 27 30 | 30 30 277 15 4 0 | + + (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) | - 30 30 27 55 15 2 0 0 | + 0 0 3 15 28 30 | - 30 30 27 15 4 0 | + 0 0 3 15 26 30 | 30 30 27 15 4 0 | + 0 0 3 15 26 30 | 30 30 27 15 3 0 | + 0 0 3 15 27 30 | 2 30 30 28 15 3 0 | 5 0 0 2 15 27 30 30 |
| Cut-off Range | + 0 0 4 16 27 30 30 | - 30 30 27 16 4 0 | + 0 0 3 14 26 30 30 SC | - 30 30 27 15 4 0 | + 0 0 0 3 15 26 30 30 | 30 30 25 14 6 0 | + 0 0 5 16 24 30 30 | - 30 30 27 15 3 0 | + 0 0 3 15 27 30 30 | 30 30 27 15 4 0 | + + (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) | 30 30 277 155 15 2 0 0 0 0 MI | + 0 0 0 3 15 28 30 30 | - 30 30 27 15 4 0 | + 0 0 3 15 26 30 30 | - 30 30 27 15 4 0 | + 0 0 3 15 26 30 30 YL | - 30 30 27 15 3 0 | + 0 0 3 15 27 30 30 | 2 30 30 28 15 3 0 | 5 + 0 0 2 15 27 30 30 |
| Cut-off Range - 0% Cut-off 3 -50% Cut-off 26 Cut-off 14 +25% Cut-off 3 +50% Cut-off 0 +300% Cut-off 0 Drug Concentration | + 0 0 4 16 27 30 30 | - 30 30 27 16 4 0 0 | + 0 0 3 14 26 30 30 S0 5 | - 30 30 27 15 4 0 0 | + 0 0 3 15 26 30 30 N 1 | 30 30 25 14 6 0 | + 0 0 5 16 24 30 30 | - 30 30 27 15 3 0 | + 0 0 3 15 27 30 30 | 30 30 27 15 4 0 | + + + (1) 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 | 30 30 27 5 15 6 2 0 0 0 MI 30 | + 0 0 0 3 15 28 30 30 | - 30 30 27 15 4 0 | + 0 0 3 15 26 30 30 | - 30 30 27 15 4 0 | + 0 0 3 15 26 30 30 YL | - 30 30 27 15 3 0 | + 0 0 3 15 27 30 30 | 2 30 30 28 15 3 0 | 5 + 0 0 2 15 27 30 30 MO 00 |
| Cut-off Range | + 0 0 4 16 27 30 30 | - 30 30 27 16 4 0 0 | + 0 0 3 14 26 30 30 S0 5 | - 30 30 27 15 4 0 0 | + 0 0 0 3 15 26 30 30 30 N 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 | 30 30 25 14 6 0 0 | + 0 0 5 16 24 30 30 | - 30 30 27 15 3 0 0 | + 0 0 3 15 27 30 30 | 30 30 27 15 4 0 0 | + + + + + + + + + + + + + + + + + + + | 300 300 277 305 300 277 305 300 300 300 300 300 300 300 300 300 | + 0 0 0 3 15 28 30 30 | - 30 30 27 15 4 0 | + 0 0 3 15 26 30 30 - - | - 30 30 27 15 4 0 | + 0 0 3 15 26 30 30 YL 00 + | - 30 30 27 15 3 0 | + 0 0 3 15 27 30 30 MO 50 + | 2 30 30 28 15 3 0 0 | 5 + 0 2 15 27 30 30 MO 00 + |
| Cut-off Range - 0% Cut-off 0% Cut-off | + 0 0 4 16 27 30 30 | - 30 30 27 16 4 0 0 | + 0 0 3 144 266 330 30 S0 5 5 30 | - 30 30 27 15 4 0 0 | + 0 0 0 3 15 26 30 30 15 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 | - 30 30 25 14 6 0 0 | + 0 0 0 5 16 24 30 30 | - 30 30 27 15 3 0 0 | + 0 0 3 15 27 30 30 2Z 1 0 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 | - 30 30 277 15 4 0 0 | + + (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) | 30 30 30 27 5 15 5 2 0 0 0 0 MI 30 30 | + 0 0 0 3 15 28 30 30 30 + 0 | - 30 30 27 15 4 0 0 MB 10 - 30 | + 0 0 3 15 26 30 30 | - 30 30 27 15 4 0 0 | + 0 0 3 15 26 30 30 YL 00 + 0 | - 30 30 27 15 3 0 0 | + 0 0 3 15 27 30 30 S50 + 0 0 | 2 30 30 28 15 3 0 0 HIM 30 | + 0 0 2 15 27 30 30 40 00 + 0 |
| Cut-off Range - 0% Cut-off 30 -50% Cut-off 36 -25% Cut-off 14 +25% Cut-off 3 +50% Cut-off 0 +300% Cut-off 0 Drug Concentration Cut-off Range 0% Cut-off -50% Cut-off | + 0 0 4 16 27 30 30 - 30 30 | - 30 30 27 16 4 0 0 | + 0 0 0 3 14 26 30 30 5 5 30 30 30 | - 30 30 30 27 15 4 0 0 0 | + 0 0 0 3 15 26 30 30 15 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 | - 30 30 25 14 6 0 0 | + 0 0 0 5 16 24 30 30 30 | - 30 30 27 15 3 0 0 | + 0 0 3 15 27 30 30 Z | - 30 30 27 15 4 0 0 0 - 30 30 | + + + 000 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 | - 30 30 27 5 15 6 2 0 0 0 0 MI 30 30 30 | + 0 0 0 3 15 28 30 30 30 = S 00 + 0 0 | - 30 30 27 15 4 0 0 - 30 30 | + 0 0 3 15 26 30 30 + 0 0 | - 30 30 27 15 4 0 0 F 30 30 | + 0 0 3 15 26 30 30 YL 00 + 0 | - 30 30 27 15 3 0 0 - 30 30 30 | + 0 0 3 15 27 30 30 30 F50 + 0 0 0 | 2 30 30 28 15 3 0 0 - 30 30 30 30 30 | 5 + 0 0 2 15 27 30 30 00 + 0 0 |
| Cut-off Range - 0% Cut-off 30 -50% Cut-off 30 -25% Cut-off 14 +25% Cut-off 3 +50% Cut-off 0 -300% Cut-off 0 -300% Cut-off 26 -50% Cut-off -50% Cut-off -25% Cut-off -25% Cut-off | + 0 0 4 16 27 30 30 30 R 1 - 30 30 27 | - 30 30 27 16 4 0 0 0 | + 0 0 3 3 14 26 30 30 SC 5 30 30 30 26 | - 30 30 30 27 15 4 0 0 | + 0 0 3 3 15 26 30 30 30 15 15 15 15 15 15 15 15 15 15 15 15 15 | - 30 30 25 14 6 0 0 | + 0 0 0 5 16 24 30 30 30 0 0 3 30 30 30 | - 30 30 27 15 3 0 0 | + 0 0 3 15 27 30 30 Z Z 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 | 30 30 27 15 4 0 0 1,0 - 30 30 27 | + + 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 | - 30 30 27 5 15 6 2 9 0 9 0 9 0 9 0 9 0 9 0 9 0 9 0 9 0 9 0 | + 0 0 0 3 15 28 30 30 30 + 0 0 0 3 | - 30 30 27 15 4 0 0 - 30 30 27 | + 0 0 3 15 26 30 30 30 + 0 0 3 | - 30 30 27 15 4 0 0 F 30 30 27 | + 0 0 3 15 26 30 30 YL 00 + 0 0 3 | - 30 30 27 15 3 0 0 - 30 30 27 15 3 3 0 2 7 | + + 0 0 0 3 155 277 330 330 PMO 250 + + 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 | 2 30 30 28 15 3 0 0 HIN 30 30 30 28 | 5 + 0 0 2 15 27 30 30 00 + + 0 0 2 |
| Cut-off Range - 0% Cut-off 30 -50% Cut-off 26 Cut-off 14 +25% Cut-off 0 +300% Cut-off 0 Drug Concentration Cut-off Range 0% Cut-off -50% Cut-off -25% Cut-off Simple Cu | + 0 0 4 16 27 30 30 30 - 30 30 27 | - 30 30 27 16 4 0 0 0 | + 0 0 3 14 26 30 30 30 55 14 30 30 30 26 14 | 30 30 27 15 4 0 0 0 0 0 0 0 0 16 16 | + 0 0 3 15 26 30 30 15 15 15 15 15 15 15 15 15 15 15 15 15 | - 30 30 25 14 6 0 0 - 0 - 0 - 0 - (0) (0) (7 35 1 | + 0 0 0 5 16 24 30 30 30 30 30 30 30 5 5 1 | - 30 30 27 15 3 0 0 0 MT2 500 | + 0 0 3 15 27 30 30 30 30 30 3 15 15 15 15 15 15 15 15 15 15 15 15 15 | - 30 30 27 15 4 0 0 0 - 30 30 27 | + + 0000 + 0000 166 | - 30 30 30 27 5 15 6 2 0 0 0 0 MI 30 30 30 27 | + 0 0 3 15 28 30 30 30 + 0 0 3 16 | - 30 30 27 15 4 0 0 - 30 30 27 14 | + 0 0 3 15 26 30 30 30 + 0 0 3 16 | - 30 30 27 15 4 0 0 - 30 30 30 27 17 | + 0 0 3 15 26 30 30 YL 00 + 0 0 3 13 | - 30 30 27 15 3 0 0 H 2 - 30 30 28 3 15 | + + 0 0 0 3 155 277 330 300 550 + 1 0 0 0 0 15 2 15 | 2 30 30 28 15 3 0 0 HMM 30 30 30 30 28 15 30 15 30 15 30 15 30 15 30 15 30 15 15 15 15 15 15 15 15 15 15 | 5 + 0 0 2 15 27 30 30 00 + 0 0 15 15 27 30 30 10 10 10 10 10 10 10 10 10 10 10 10 10 |
| Cut-off Range - 0% Cut-off 30 -50% Cut-off 26 Cut-off 14 +25% Cut-off 3 +50% Cut-off 0 +300% Cut-off 0 Drug Concentration Cut-off Range 0% Cut-off -50% Cut-off -25% Cut-off | + 0 0 4 16 27 30 30 - 30 30 27 15 4 | - 30 30 27 16 4 0 0 0 PD 50 + + 0 0 0 3 3 16 4 1 5 0 0 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 | + 0 0 3 144 266 30 30 30 55 144 30 30 30 30 30 30 30 30 30 30 30 30 30 | - 30 30 27 15 4 0 0 0 | + 0 0 3 15 26 30 30 15 30 15 30 15 7 4 | 30 30 25 14 6 0 0 0 NNE 0,000 7 3 5 1 2 | + 0 0 5 16 24 30 30 30 0 3 0 3 3 2 5 1 6 4 | - 30 30 27 15 3 0 0 0 MT2 50 | + 0 0 3 15 27 30 30 30 2 Z 0 0 15 15 15 15 15 15 15 15 15 15 15 15 15 | - 30 30 27 15 4 0 0 0 - 30 30 27 14 4 | + + (1) 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 | - 30 30 30 27 5 15 6 2 9 0 9 0 9 0 9 0 9 0 9 0 9 0 9 0 9 0 9 0 | + 0 0 3 15 28 30 30 30 + 0 0 0 3 16 25 | - 30 30 27 15 4 0 0 - 30 30 27 14 4 | + 0 0 3 15 26 30 30 30 + 0 0 0 3 16 26 | - 30 30 27 15 4 0 0 F 30 30 27 17 4 | + 0 0 3 15 26 30 30 YL 00 + 0 0 0 3 13 26 | - 30 30 27 15 3 0 0 H 2 30 30 30 27 15 3 15 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 | + + 0 0 0 3 15 27 30 30 S S S S S S S S S S S S S S S S S | 2 30 30 28 15 3 0 0 HIM 30 30 30 28 15 28 15 28 15 20 20 20 20 20 20 20 20 20 20 | 5 + 0 0 2 15 27 30 30 00 + 0 0 15 27 27 27 27 27 27 27 27 27 27 27 27 27 |
| Cut-off Range - 0% Cut-off 30 -50% Cut-off 26 Cut-off 14 +25% Cut-off 0 +300% Cut-off 0 Drug Concentration Cut-off Range 0% Cut-off -50% Cut-off -25% Cut-off Simple Cu | + 0 0 4 16 27 30 30 30 - 30 30 27 | - 30 30 27 16 4 0 0 0 | + 0 0 3 114 26 30 30 30 30 30 26 14 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 | 30 30 27 15 4 0 0 0 0 0 0 0 0 16 16 | + 0 0 0 3 15 26 30 30 30 30 27 4 4 0 0 0 | - 30 30 25 14 6 0 0 - 0 - 0 - 0 - 0 - 0 - 0 - 0 - 0 - 0 | + 0 0 0 5 16 24 30 30 30 30 30 33 25 16 6 4 0 0 0 | - 30 30 27 15 3 0 0 0 | + 0 0 3 15 27 30 30 30 27 30 30 30 30 30 | - 30 30 27 15 4 0 0 0 - 30 30 27 | + + 0000 + 0000 166 | - 30 30 30 27 5 15 6 2 0 0 0 0 MI 30 30 30 27 | + 0 0 3 15 28 30 30 30 + 0 0 3 16 | - 30 30 27 15 4 0 0 - 30 30 27 14 | + 0 0 3 15 26 30 30 30 + 0 0 3 16 | - 30 30 27 15 4 0 0 - 30 30 30 27 17 | + 0 0 3 15 26 30 30 YL 00 + 0 0 3 13 | - 30 30 27 15 3 0 0 - 30 30 28 315 3 30 28 30 30 27 | + + 0 0 0 3 155 277 330 300 550 + 1 0 0 0 0 15 2 15 | 2 30 30 28 15 3 0 0 HMM 30 30 30 30 28 15 30 15 30 15 30 15 30 15 30 15 30 15 15 15 15 15 15 15 15 15 15 | 5 + 0 0 2 15 27 30 30 WO 00 + 0 |

in urine by the Multi-Drug Rapid Test at 5 minutes.

| Analytes | conc. (ng/r | nL) Analytes | conc. (ng/mL) |
|-------------------------|-------------|------------------|---------------|
| | ACETAMINOP | PHEN (ACE 5,000) | |
| Acetaminophen | 5,000 | | |
| | AMPHETAM | INE (AMP 1,000) | |
| D,L-Amphetamine sulfate | 300 | Phentermine | 1,000 |
| L-Amphetamine | 25,000 | Maprotiline | 50,000 |
| (±) 3,4-Methylenedioxy | 500 | Methoxyphenamine | 6,000 |
| amphetamine | 500 | D-Amphetamine | 1,000 |
| | AMPHETAN | IINE (AMP 500) | |
| D,L-Amphetamine sulfate | 150 | Phentermine | 500 |
| L-Amphetamine | 12,500 | Maprotiline | 25,000 |
| (±) 3,4-Methylenedioxy | 250 | Methoxyphenamine | 3,000 |
| amphetamine | 230 | D-Amphetamine | 500 |

| | | MINE (AMP 300) | |
|-------------------------|------------|---------------------|----------|
| D,L-Amphetamine sulfate | 75 | Phentermine | 300 |
| L-Amphetamine | 10,000 | Maprotiline | 15,000 |
| (±) 3,4-Methylenedioxy | 150 | Methoxyphenamine | 2,000 |
| amphetamine | | D-Amphetamine | 300 |
| | | ATES (BAR 300) | |
| Amobarbital | 5,000 | Alphenol | 600 |
| 5,5-Diphenylhydantoin | 8,000 | Aprobarbital | 500 |
| Allobarbital | 600 | Butabarbital | 200 |
| Barbital | 8,000 | Butalbital | 8,000 |
| Falbutal Falbutal | 200 | Butethal | 500 |
| Cyclopentobarbital | 30,000 | Phenobarbital | 300 |
| Pentobarbital | 8,000 | Secobarbital | 300 |
| | BARBITUR | ATES (BAR 200) | |
| Amobarbital | 3,000 | Alphenol | 400 |
| 5,5-Diphenylhydantoin | 5,000 | Aprobarbital | 300 |
| Allobarbital | 400 | Butabarbital | 150 |
| Barbital | 5,000 | Butalbital | 5,000 |
| Talbutal Talbutal | 150 | Butethal | 300 |
| Cyclopentobarbital | 20,000 | Phenobarbital | 200 |
| Pentobarbital | 5,000 | Secobarbital | 200 |
| | BENZODIAZE | PINES (BZO 500) | |
| Alprazolam | 200 | Bromazepam | 1,500 |
| a-hydroxyalprazolam | 2,500 | Chlordiazepoxide | 1,500 |
| Clobazam | 300 | Nitrazepam | 300 |
| Clonazepam | 800 | Norchlordiazepoxide | 200 |
| Clorazepatedipotassium | 800 | Nordiazepam | 1,500 |
| Delorazepam | 1,500 | Oxazepam | 500 |
| Desalkylflurazepam | 300 | Temazepam | 300 |
| Flunitrazepam | 300 | Diazepam | 500 |
| ±) Lorazepam | 5,000 | Estazolam | 10,000 |
| RS-Lorazepamglucuronide | 300 | Triazolam | 5,000 |
| Midazolam | 10,000 | | ,,,,,, |
| | | PINES (BZO 300) | L |
| Alprazolam | 100 | Bromazepam | 900 |
| a-hydroxyalprazolam | 1,500 | Chlordiazepoxide | 900 |
| Clobazam | 200 | Nitrazepam | 200 |
| Clonazepam | 500 | Norchlordiazepoxide | 100 |
| Clorazepatedipotassium | 500 | Nordiazepam | 900 |
| Delorazepam | 900 | Oxazepam | 300 |
| Desalkylflurazepam | 200 | Temazepam | 100 |
| Flunitrazepam | 200 | Diazepam | 300 |
| ±) Lorazepam | 3,000 | Estazolam | 6,000 |
| RS-Lorazepamglucuronide | 200 | Triazolam | 3,000 |
| Midazolam | 6,000 | mazoiam | 3,000 |
| | | EPINES (BZO 200) | <u> </u> |
| Alprazolam | 70 | Bromazepam | 600 |
| ' | | · · | |
| a-hydroxyalprazolam | 1,000 | Chlordiazepoxide | 600 |
| Clobazam | 120 | Nitrazepam | 120 |
| Clonazepam | 300 | Norchlordiazepoxide | 70 |
| Clorazepatedipotassium | 300 | Nordiazepam | 600 |
| Delorazepam | 600 | Oxazepam | 200 |
| Desalkylflurazepam | 120 | Temazepam | 70 |
| Flunitrazepam | 120 | Diazepam | 200 |
| ±) Lorazepam | 2,000 | Estazolam | 4,000 |
| RS-Lorazepamglucuronide | 120 | Triazolam | 2,000 |
| Midazolam | 4,000 | | |
| | | PINES (BZO 100) | |
| Alprazolam | 40 | Bromazepam | 300 |
| a-hydroxyalprazolam | 500 | Chlordiazepoxide | 300 |
| Clobazam | 60 | Nitrazepam | 60 |
| Clonazepam | 150 | Norchlordiazepoxide | 40 |

| Clorazepatedipotassium | 150 | Nordiazepam | 300 |
|---|---------------|---------------------------------------|---------|
| Delorazepam | 300 | Oxazepam | 100 |
| Desalkylflurazepam | 60 | Temazepam | 40 |
| Flunitrazepam | 60 | Diazepam | 100 |
| (±) Lorazepam | 1,000 | Estazolam | 2,000 |
| RS-Lorazepamglucuronide | 60 | Triazolam | 1,000 |
| Midazolam | 2,000 | | , |
| | BUPRENORPHI | NF (BUP 10) | 1 |
| Buprenorphine | 10 | Norbuprenorphine | 50 |
| Вартепогріште | 10 | Norbuprenorphine | |
| Buprenorphine 3-D-Glucuronide | 50 | 3-D-Glucuronide | 100 |
| | BUPRENORPH | | I . |
| Buprenorphine | 5 | Norbuprenorphine | 25 |
| Виргеногріппе | 5 | Norbuprenorphine | 23 |
| Buprenorphine 3-D-Glucuronide | 25 | 3-D-Glucuronide | 50 |
| | COCAINE (C | | 1 |
| Dansadaasanina | | | 100.000 |
| Benzoylecgonine | 1,500 1200 | Cocaethylene | 100,000 |
| Cocaine HCI | | Ecgonine | 150,000 |
| | COCAINE (C | | 00.000 |
| Benzoylecgonine | 300 | Cocaethylene | 20,000 |
| Cocaine HCI | 200 | Ecgonine | 30,000 |
| | COCAINE (C | | T |
| Benzoylecgonine | 200 | Cocaethylene | 13,500 |
| Cocaine HCI | 135 | Ecgonine | 20,000 |
| | COCAINE (C | · · · · · · · · · · · · · · · · · · · | |
| Benzoylecgonine | 150 | Cocaethylene | 1,0000 |
| Cocaine HCI | 120 | Ecgonine | 15,000 |
| | COCAINE (C | OC 100) | |
| Benzoylecgonine | 100 | Cocaethylene | 7,000 |
| Cocaine HCI | 80 | Ecgonine | 10,000 |
| | MARIJUANA | (THC 300) | |
| Cannabinol | 200,000 | ∆ ⁸ -THC | 100,000 |
| 11-nor-△ ⁸ -THC-9 COOH | 200 | Δ ⁹ -THC | 100,000 |
| 11-nor-△ ⁹ -THC-9 COOH | 300 | | |
| | MARIJUANA | (THC 200) | 1 |
| Cannabinol | 140,000 | ∆ ⁸ -THC | 68,000 |
| 11-nor-△ ⁸ -THC-9 COOH | 120 | ∆ ⁹ -THC | 68,000 |
| 11-nor-Δ ⁹ -THC-9 COOH | 200 | | |
| 11.00 2 11.00 00011 | MARIJUANA | (THC 150) | ı |
| Cannabinol | 100,000 | △ ⁸ -THC | 50,000 |
| 11-nor- Δ^8 -THC-9 COOH | 100,000 | Δ ⁹ -THC | 50,000 |
| 11-nor-Δ ⁹ -THC-9 COOH | 150 | 4 1110 | 55,000 |
| 11-101-2 -1110-9 00011 | MARIJUANA | (THC 50) | ı |
| Canadinal | 35,000 | Δ ⁸ -THC | 17,000 |
| Cannabinol 11-nor-∆ ⁸ -THC-9 COOH | 35,000 | Δ ⁹ -THC | 17,000 |
| 11-nor-Δ*-THC-9 COOH | | Δ -1 ΠC | 17,000 |
| I I-nor-Δ - I HC-9 COOH | 50 | (THO 00) | 1 |
| | MARIJUANA | | 40.000 |
| Cannabinol | 20,000 | Δ ⁸ -THC | 10,000 |
| 11-nor-△ ⁸ -THC-9 COOH | 20 | Δ ⁹ -THC | 10,000 |
| 11-nor-△ ⁹ -THC-9 COOH | 30 | | |
| | MARIJUANA | | 1 |
| Cannabinol | 17,500 | ∆ ⁸ -THC | 8,500 |
| 11-nor-Δ ⁸ -THC-9 COOH | 15 | Δ ⁹ -THC | 8,500 |
| 11-nor-△ ⁹ -THC-9 COOH | 25 | | |
| | MARIJUANA | | |
| Cannabinol | 14,000 | ∆ ⁸ -THC | 6,800 |
| 11-nor-∆ ⁸ -THC-9 COOH | 12 | ∆ ⁹ -THC | 6,800 |
| 11-nor-△ ⁹ -THC-9 COOH | 20 | | |
| | METHADONE | (MTD 300) | |
| Methadone | 300 | Doxylamine | 100,000 |
| | METHADONE | | • |
| Methadone | 200 | Doxylamine | 65,000 |
| | METHADONE | | |
| L | | | |

| Methadone | 100 | Doxylamine | 32,500 |
|--|-----------------|---------------------------|------------------|
| | • | NE (MET 1, 000) | 02,000 |
| o-Hydroxymethamphetamine | 25,000 | (±)-3,4-Methylenedioxy- | |
| D-Methamphetamine | 1,000 | methamphetamine | 12,500 |
| L-Methamphetamine | 20,000 | Mephentermine | 50,000 |
| · · · · · · · · · · · · · · · · · · · | • | MINE (MET 500) | 1 - |
| o-Hydroxymethamphetamine | 12,500 | (±)-3,4-Methylenedioxy- | 0.050 |
| D-Methamphetamine | 500 | methamphetamine | 6,250 |
| L-Methamphetamine | 10,000 | Mephentermine | 25,000 |
| ME | THAMPHETAN | MINE (MET 300) | • |
| o-Hydroxymethamphetamine | 7,500 | (±)-3,4-Methylenedioxy- | 0.750 |
| D-Methamphetamine | 300 | methamphetamine | 3,750 |
| L-Methamphetamine | 6,000 | Mephentermine | 15,000 |
| ME | THAMPHETAN | MINE (MET 200) | |
| o-Hydroxymethamphetamine | 5,000 | (±)-3,4-Methylenedioxy- | 2 500 |
| D-Methamphetamine | 200 | methamphetamine | 2,500 |
| L-Methamphetamine | 4,000 | Mephentermine | 10,000 |
| METHYLENEDIOXY | METHAMPHET | TAMINE (MDMA 1, 000) Ecst | asy |
| (±) 3,4-Methylenedioxy- | 1 000 | 3,4-Methylenedioxyethyl- | 600 |
| methamphetamine HCI | 1,000 | amphetamine | 600 |
| (±) 3,4-Methylenedioxyampheta | 6,000 | | |
| mine HCI | -,000 | | |
| | YMETHAMPHE | TAMINE (MDMA 500) Ecsta | sy |
| (±) 3,4-Methylenedioxy- | 500 | 3,4-Methylenedioxyethyl- | 300 |
| methamphetamine HCI | | amphetamine | |
| (±) 3,4-Methylenedioxyampheta | 3,000 | | |
| mine HCI | | | |
| | YMETHAMPHE | TAMINE (MDMA 300) Ecsta | sy |
| (±) 3,4-Methylenedioxy- | 300 | 3,4-Methylenedioxyethyl- | 180 |
| methamphetamine HCI | + | amphetamine | |
| (±) 3,4-Methylenedioxyampheta mine HCI | 1,800 | | |
| | MORPHINE (M | OP/OPI 300) | |
| Codeine | 200 | Norcodeine | 6,000 |
| Levorphanol | 1,500 | Normorphone | 50,000 |
| Morphine-3-β-D-Glucuronide | 800 | Oxycodone | 30,000 |
| Ethylmorphine | 6,000 | Oxymorphone | 50,000 |
| Hydrocodone | 50,000 | Procaine | 15,000 |
| Hydromorphone | 3,000 | Thebaine | 6,000 |
| 6-Monoacethylmorphine | 300 | Morphine | 300 |
| | MORPHINE (M | | 500 |
| Codeine | 160 | Norcodeine | 4,000 |
| Levorphanol | 1,000 | Normorphone | 40,000 |
| Morphine-3-β-D-Glucuronide | 600 | Oxycodone | 20,000 |
| Ethylmorphine | 4,000 | Oxymorphone | 40,000 |
| Hydrocodone | 40,000 | Procaine | 10,000 |
| Hydromorphone | 2,000 | Thebaine | 4,000 |
| 6-Monoacethylmorphine | 200 | Morphine | 200 |
| | MORPHINE (M | · · · | |
| Codeine | 80 | Norcodeine | 2,000 |
| Levorphanol | 500 | Normorphone | 20,000 |
| Morphine-3-β-D-Glucuronide | 300 | Oxycodone | 10,000 |
| Ethylmorphine | 2,000 | Oxymorphone | 20,000 |
| Hydrocodone | 20,000 | Procaine | 5,000 |
| Hydromorphone | 1,000 | Thebaine | 2,000 |
| 6-Monoacethylmorphine | 200 | Morphine | 100 |
| | METHAQUALON | | 1.22 |
| Methaqualone | 300 | ,, | |
| | ORPHINE/OPIA | TE (OPI 2.000) | 1 |
| | | Morphine | 2,000 |
| Codeine | 2.000 | | -, |
| | 2,000 3.000 | • | 25.000 |
| Codeine Ethylmorphine Hydrocodone | 3,000 50,000 | Norcodeine Normorphone | 25,000 50,000 |

| Levorphanol | 25,000 | Oxymorphone | 25,000 |
|-----------------------------------|------------------|--|-------------------|
| 6-Monoacetylmorphine | 3,000 | Procaine | 50,000 |
| Morphine 3-β-D-glucuronide | 2,000 | Thebaine | 25,000 |
| ı | MORPHINE/O | PIATE (OPI 1,000) | |
| Codeine | 1,000 | Morphine | 1,000 |
| Ethylmorphine | 1,500 | Norcodeine | 12,500 |
| Hydrocodone | 25,000 | Normorphone | 25,000 |
| Hydromorphone | 7,500 | Oxycodone | 12,500 |
| Levorphanol | 12,500 | Oxymorphone | 12,500 |
| 6-Monoacetylmorphine | 1,500 | Procaine | 25,000 |
| Morphine 3-β-D-glucuronide | 1,000 | Thebaine | 12,500 |
| | | NE (MPRD 100) | |
| Normeperidine | 100 | Meperidine | 100 |
| | | IDINE (PCP 50) | |
| Phencyclidine | 50 | 4-Hydroxyphencyclidine | 25,000 |
| | | IDINE (PCP 25) | |
| Phencyclidine | 25 | 4-Hydroxyphencyclidine | 12,500 |
| | | HENE (PPX 300) | |
| D-Propoxyphene | 300 | D-Norpropoxyphene | 300 |
| | | PRESSANTS (TCA 1,000) | |
| Nortriptyline | 1,000 | Imipramine | 400 |
| Nordoxepine | 500 | Clomipramine | 50,000 |
| Trimipramine | 3,000 | Doxepine | 2,000 |
| Amitriptyline | 1,500 | Maprotiline | 2,000 |
| Promazine | 3,000 | Promethazine | 50,000 |
| Desipramine | 200 | Perphenazine | 50,000 |
| Cyclobenzaprine | 2,000 | Dithiaden | 10,000 |
| TRICY | | PRESSANTS (TCA 500) | |
| Nortriptyline | 500 | Imipramine | 200 |
| Nordoxepine | 250 | Clomipramine | 25,000 |
| Trimipramine | 1,500 | Doxepine | 1,000 |
| Amitriptyline | 750 | Maprotiline | 1,000 |
| Promazine | 1,500 | Promethazine | 25,000 |
| Desipramine | 100 | Perphenazine | 25,000 |
| Cyclobenzaprine | 1,000 | Dithiaden | 5,000 |
| | | PRESSANTS (TCA 300) | 400 |
| Nortriptyline | 300 | Imipramine | 120 |
| Nordoxepine | 150 | Clomipramine | 15,000 |
| Trimipramine | 900 | Doxepine | 600 |
| Amitriptyline | 450 | Maprotiline | 600 |
| Promazine | 900 | Promethazine | 15,000 |
| Desipramine Cualches and and a | 60 | Perphenazine | 15,000 |
| Cyclobenzaprine | 600 TD 4M 4 D | Dithiaden | 3,000 |
| n Doomothyl sig tramadal | 200 | OL (TML 100) | 10.000 |
| n-Desmethyl-cis-tramadol | | o-Desmethyl-cis-tramadol | 10,000 |
| Cis-tramadol Procyclidine | 100,000 | Phencyclidine | 100,000 50,000 |
| Procyclidine | | d,I-O-Desmethyl venlafaxine | 50,000 |
| - Deamethyl sig transadal | | OL (TML 200) | 20,000 |
| n-Desmethyl-cis-tramadol | 400 | o-Desmethyl-cis-tramadol | 20,000 |
| Cis-tramadol | 200 | Phencyclidine | 200,000 |
| Procyclidine | 200,000 | d,I-O-Desmethyl venlafaxine | 100,000 |
| - Deamethyl sig transadal | 600 | OL (TML 300) | 20,000 |
| n-Desmethyl-cis-tramadol | | o-Desmethyl-cis-tramadol | 30,000 |
| Cis-tramadol Procyclidine | 300 300,000 | Phencyclidine | 300,000 |
| rrocycliume | | d,I-O-Desmethyl venlafaxine | 150,000 |
| n Doomothyl oic tramadal | | Desmethyl eig tramadal | E0 000 |
| n-Desmethyl-cis-tramadol | 10,00 | o-Desmethyl-cis-tramadol | 50,000 |
| Cis-tramadol Procyclidino | 500 000 | Phencyclidine | 500,000 |
| Procyclidine | 500,000 | d,I-O-Desmethyl venlafaxine | 250,000 |
| Votomino | | E (KET 1, 000) | 25 000 |
| Ketamine Dovtromethershop | 1,000 | Benzphetamine | 25,000 |
| Dextromethorphan | 2,000 | (+) Chlorpheniramine | 25,000 |

| L | | a | |
|---|---|---|---|
| Methoxyphenamine | 25,000 | Clonidine | 100,000 |
| d-Norpropoxyphene | 25,000 | EDDP | 50,000 |
| Promazine | 25,000 | 4-Hydroxyphencyclidine | 50,000 |
| Promethazine | 25,000 | Levorphanol | 50,000 |
| Pentazocine | 25,000 | MDE | 50,000 |
| Phencyclidine | 25,000 | Meperidine | 25,000 |
| Tetrahydrozoline | 500 | d-Methamphetamine | 50,000 |
| Mephentermine | 25,000 | I-Methamphetamine | 50,000 |
| | 20,000 | 3,4-Methylendioxymetham- | 00,000 |
| (1R, 2S) - (-)-Ephedrine | 100,000 | phetamine (MDMA) | 100,000 |
| Disopyramide | 25,000 | Thioridazine | 50,000 |
| | KETAMINE (I | KET 500) | |
| Ketamine | 500 | Benzphetamine | 12,500 |
| Dextromethorphan | 1,000 | (+) Chlorpheniramine | 12,500 |
| Methoxyphenamine | 12,500 | Clonidine | 50,000 |
| d-Norpropoxyphene | 12,500 | EDDP | 25,000 |
| Promazine | 12,500 | 4-Hydroxyphencyclidine | 25,000 |
| Promethazine | 12,500 | Levorphanol | 25,000 |
| | | MDE | |
| Pentazocine Disassassississas | 12,500 | | 25,000 |
| Phencyclidine | 12,500 | Meperidine | 12,500 |
| Tetrahydrozoline | 250 | d-Methamphetamine | 25,000 |
| Mephentermine | 12,500 | I-Methamphetamine | 25,000 |
| (1R, 2S) - (-)-Ephedrine | 50,000 | 3,4-Methylendioxymetham- | 50,000 |
| (1K, 23) - (-)-Ephedilile | 50,000 | phetamine (MDMA) | 30,000 |
| Disopyramide | 12,500 | Thioridazine | 25,000 |
| | KETAMINE (I | KET 300) | • |
| Ketamine | 300 | Benzphetamine | 6,250 |
| Dextromethorphan | 600 | (+) Chlorpheniramine | 6,250 |
| Methoxyphenamine | 6,250 | Clonidine | 30,000 |
| d-Norpropoxyphene | 6,250 | EDDP | 15,000 |
| | | | |
| Promazine | 6,250 | 4-Hydroxyphencyclidine | 15,000 |
| Promethazine | 6,250 | Levorphanol | 15,000 |
| Pentazocine | 6,250 | MDE | 15,000 |
| | | | |
| Phencyclidine | 6,250 | Meperidine | 6,250 |
| | 6,250 150 | Meperidine d-Methamphetamine | 6,250 15,000 |
| Phencyclidine | | | |
| Phencyclidine Tetrahydrozoline | 150 | d-Methamphetamine I-Methamphetamine 3,4-Methylendioxymetham- | 15,000 |
| Phencyclidine Tetrahydrozoline Mephentermine (1R, 2S) - (-)-Ephedrine | 150 6,250 30,000 | d-Methamphetamine I-Methamphetamine 3,4-Methylendioxymetham- phetamine (MDMA) | 15,000 15,000 30,000 |
| Phencyclidine Tetrahydrozoline Mephentermine | 150 6,250 30,000 6,250 | d-Methamphetamine I-Methamphetamine 3,4-Methylendioxymetham- phetamine (MDMA) Thioridazine | 15,000 15,000 |
| Phencyclidine Tetrahydrozoline Mephentermine (1R, 2S) - (-)-Ephedrine Disopyramide | 150 6,250 30,000 6,250 KETAMINE (I | d-Methamphetamine I-Methamphetamine 3,4-Methylendioxymetham- phetamine (MDMA) Thioridazine KET 100) | 15,000 15,000 30,000 15,000 |
| Phencyclidine Tetrahydrozoline Mephentermine (1R, 2S) - (-)-Ephedrine Disopyramide Ketamine | 150 6,250 30,000 6,250 KETAMINE (I | d-Methamphetamine I-Methamphetamine 3,4-Methylendioxymetham- phetamine (MDMA) Thioridazine KET 100) Benzphetamine | 15,000 15,000 30,000 15,000 |
| Phencyclidine Tetrahydrozoline Mephentermine (1R, 2S) - (-)-Ephedrine Disopyramide Ketamine Dextromethorphan | 150 6,250 30,000 6,250 KETAMINE (I 100 200 | d-Methamphetamine I-Methamphetamine 3,4-Methylendioxymetham- phetamine (MDMA) Thioridazine KET 100) Benzphetamine (+) Chlorpheniramine | 15,000 15,000 30,000 15,000 2,000 2,000 |
| Phencyclidine Tetrahydrozoline Mephentermine (1R, 2S) - (-)-Ephedrine Disopyramide Ketamine Dextromethorphan Methoxyphenamine | 150 6,250 30,000 6,250 KETAMINE (I 100 200 2,000 | d-Methamphetamine I-Methamphetamine 3,4-Methylendioxymetham- phetamine (MDMA) Thioridazine KET 100) Benzphetamine (+) Chlorpheniramine Clonidine | 15,000 15,000 30,000 15,000 2,000 2,000 10,000 |
| Phencyclidine Tetrahydrozoline Mephentermine (1R, 2S) - (-)-Ephedrine Disopyramide Ketamine Dextromethorphan Methoxyphenamine d-Norpropoxyphene | 150 6,250 30,000 6,250 KETAMINE (I 100 200 2,000 2,000 | d-Methamphetamine I-Methamphetamine 3,4-Methylendioxymetham- phetamine (MDMA) Thioridazine KET 100) Benzphetamine (+) Chlorpheniramine Clonidine EDDP | 15,000 15,000 30,000 15,000 2,000 2,000 10,000 5,000 |
| Phencyclidine Tetrahydrozoline Mephentermine (1R, 2S) - (-)-Ephedrine Disopyramide Ketamine Dextromethorphan Methoxyphenamine d-Norpropoxyphene Promazine | 150 6,250 30,000 6,250 KETAMINE (I 100 200 2,000 2,000 2,000 | d-Methamphetamine I-Methamphetamine 3,4-Methylendioxymethamphetamine (MDMA) Thioridazine KET 100) Benzphetamine (+) Chlorpheniramine Clonidine EDDP 4-Hydroxyphencyclidine | 15,000 15,000 30,000 15,000 2,000 2,000 10,000 5,000 5,000 |
| Phencyclidine Tetrahydrozoline Mephentermine (1R, 2S) - (-)-Ephedrine Disopyramide Ketamine Dextromethorphan Methoxyphenamine d-Norpropoxyphene Promazine Promethazine | 150 6,250 30,000 6,250 KETAMINE (I 100 200 2,000 2,000 | d-Methamphetamine l-Methamphetamine 3,4-Methylendioxymetham- phetamine (MDMA) Thioridazine KET 100) Benzphetamine (+) Chlorpheniramine Clonidine EDDP 4-Hydroxyphencyclidine Levorphanol | 15,000 15,000 30,000 15,000 2,000 2,000 10,000 5,000 5,000 |
| Phencyclidine Tetrahydrozoline Mephentermine (1R, 2S) - (-)-Ephedrine Disopyramide Ketamine Dextromethorphan Methoxyphenamine d-Norpropoxyphene Promazine | 150 6,250 30,000 6,250 KETAMINE (I 100 200 2,000 2,000 2,000 | d-Methamphetamine I-Methamphetamine 3,4-Methylendioxymethamphetamine (MDMA) Thioridazine KET 100) Benzphetamine (+) Chlorpheniramine Clonidine EDDP 4-Hydroxyphencyclidine | 15,000 15,000 30,000 15,000 2,000 2,000 10,000 5,000 5,000 |
| Phencyclidine Tetrahydrozoline Mephentermine (1R, 2S) - (-)-Ephedrine Disopyramide Ketamine Dextromethorphan Methoxyphenamine d-Norpropoxyphene Promazine Promethazine | 150 6,250 30,000 6,250 KETAMINE (I 100 200 2,000 2,000 2,000 2,000 2,000 | d-Methamphetamine l-Methamphetamine 3,4-Methylendioxymetham- phetamine (MDMA) Thioridazine KET 100) Benzphetamine (+) Chlorpheniramine Clonidine EDDP 4-Hydroxyphencyclidine Levorphanol | 15,000 15,000 30,000 15,000 2,000 2,000 10,000 5,000 5,000 |
| Phencyclidine Tetrahydrozoline Mephentermine (1R, 2S) - (-)-Ephedrine Disopyramide Ketamine Dextromethorphan Methoxyphenamine d-Norpropoxyphene Promazine Promethazine Pentazocine | 150 6,250 30,000 6,250 KETAMINE (I 100 200 2,000 2,000 2,000 2,000 2,000 2,000 | d-Methamphetamine l-Methamphetamine 3,4-Methylendioxymetham- phetamine (MDMA) Thioridazine KET 100) Benzphetamine (-) Chlorpheniramine Clonidine EDDP 4-Hydroxyphencyclidine Levorphanol MDE | 15,000 15,000 30,000 15,000 2,000 2,000 10,000 5,000 5,000 5,000 5,000 |
| Phencyclidine Tetrahydrozoline Mephentermine (1R, 2S) - (-)-Ephedrine Disopyramide Ketamine Dextromethorphan Methoxyphenamine d-Norpropoxyphene Promazine Pentazocine Phencyclidine | 150 6,250 30,000 6,250 KETAMINE (I 100 200 2,000 2,000 2,000 2,000 2,000 2,000 2,000 | d-Methamphetamine l-Methamphetamine 3,4-Methylendioxymetham- phetamine (MDMA) Thioridazine KET 100) Benzphetamine (+) Chlorpheniramine Clonidine EDDP 4-Hydroxyphencyclidine Levorphanol MDE Meperidine | 15,000 15,000 30,000 15,000 2,000 10,000 5,000 5,000 5,000 5,000 2,000 |
| Phencyclidine Tetrahydrozoline Mephentermine (1R, 2S) - (-)-Ephedrine Disopyramide Ketamine Dextromethorphan Methoxyphenamine d-Norpropoxyphene Promazine Promethazine Pentazocine Phencyclidine Tetrahydrozoline Mephentermine | 150 6,250 30,000 6,250 KETAMINE (I 100 200 2,000 2,000 2,000 2,000 2,000 2,000 2,000 2,000 2,000 2,000 2,000 | d-Methamphetamine I-Methamphetamine 3,4-Methylendioxymetham- phetamine (MDMA) Thioridazine KET 100) Benzphetamine (+) Chlorpheniramine Clonidine EDDP 4-Hydroxyphencyclidine Levorphanol MDE Meperidine d-Methamphetamine I-Methamphetamine | 15,000 15,000 30,000 15,000 2,000 2,000 10,000 5,000 5,000 5,000 2,000 5,000 5,000 5,000 5,000 5,000 5,000 |
| Phencyclidine Tetrahydrozoline Mephentermine (1R, 2S) - (-)-Ephedrine Disopyramide Ketamine Dextromethorphan Methoxyphenamine d-Norpropoxyphene Promazine Pentazocine Phencyclidine Tetrahydrozoline | 150 6,250 30,000 6,250 KETAMINE (I 100 200 2,000 2,000 2,000 2,000 2,000 2,000 2,000 2,000 2,000 10,000 | d-Methamphetamine I-Methamphetamine 3,4-Methylendioxymethamphetamine (MDMA) Thioridazine KET 100) Benzphetamine (+) Chlorpheniramine Clonidine EDDP 4-Hydroxyphencyclidine Levorphanol MDE Meperidine d-Methamphetamine I-Methamphetamine Thioridazine 3,4-Methylendioxymetham- | 15,000 15,000 30,000 15,000 2,000 2,000 10,000 5,000 5,000 5,000 5,000 5,000 5,000 5,000 |
| Phencyclidine Tetrahydrozoline Mephentermine (1R, 2S) - (-)-Ephedrine Disopyramide Ketamine Dextromethorphan Methoxyphenamine d-Norpropoxyphene Promazine Promethazine Pentazocine Phencyclidine Tetrahydrozoline Mephentermine (1R, 2S) - (-)-Ephedrine | 150 6,250 30,000 6,250 KETAMINE (I 100 200 2,000 2,000 2,000 2,000 2,000 2,000 2,000 2,000 10,000 2,000 | d-Methamphetamine I-Methamphetamine 3,4-Methylendioxymethamphetamine (MDMA) Thioridazine (KET 100) Benzphetamine (+) Chlorpheniramine Clonidine EDDP 4-Hydroxyphencyclidine Levorphanol MDE Meperidine d-Methamphetamine I-Methamphetamine Thioridazine 3,4-Methylendioxymethamphetamine (MDMA) | 15,000 15,000 30,000 15,000 2,000 2,000 10,000 5,000 5,000 5,000 2,000 5,000 5,000 5,000 5,000 5,000 5,000 5,000 5,000 |
| Phencyclidine Tetrahydrozoline Mephentermine (1R, 2S) - (-)-Ephedrine Disopyramide Ketamine Dextromethorphan Methoxyphenamine d-Norpropoxyphene Promazine Promethazine Pentazocine Phencyclidine Tetrahydrozoline Mephentermine (1R, 2S) - (-)-Ephedrine Disopyramide | 150 6,250 30,000 6,250 KETAMINE (I 100 200 2,000 2,000 2,000 2,000 2,000 2,000 5,000 10,000 2,000 2,000 0XYCODONE | d-Methamphetamine I-Methamphetamine 3,4-Methylendioxymethamphetamine (MDMA) Thioridazine KET 100) Benzphetamine (+) Chlorpheniramine Clonidine EDDP 4-Hydroxyphencyclidine Levorphanol MDE Meperidine d-Methamphetamine I-Methamphetamine Thioridazine 3,4-Methylendioxymethamphetamine (MDMA) (OXY 300) | 15,000 15,000 30,000 15,000 2,000 2,000 10,000 5,000 5,000 5,000 2,000 5,000 5,000 10,000 10,000 |
| Phencyclidine Tetrahydrozoline Mephentermine (1R, 2S) - (-)-Ephedrine Disopyramide Ketamine Dextromethorphan Methoxyphenamine d-Norpropoxyphene Promazine Promethazine Pentazocine Phencyclidine Tetrahydrozoline Mephentermine (1R, 2S) - (-)-Ephedrine | 150 6,250 30,000 6,250 KETAMINE (I 100 200 2,000 2,000 2,000 2,000 2,000 2,000 2,000 2,000 10,000 2,000 | d-Methamphetamine I-Methamphetamine 3,4-Methylendioxymethamphetamine (MDMA) Thioridazine (KET 100) Benzphetamine (+) Chlorpheniramine Clonidine EDDP 4-Hydroxyphencyclidine Levorphanol MDE Meperidine d-Methamphetamine I-Methamphetamine Thioridazine 3,4-Methylendioxymethamphetamine (MDMA) | 15,000 15,000 30,000 15,000 2,000 2,000 10,000 5,000 5,000 5,000 2,000 5,000 5,000 5,000 5,000 5,000 5,000 5,000 5,000 |
| Phencyclidine Tetrahydrozoline Mephentermine (1R, 2S) - (-)-Ephedrine Disopyramide Ketamine Dextromethorphan Methoxyphenamine d-Norpropoxyphene Promazine Promethazine Pentazocine Phencyclidine Tetrahydrozoline Mephentermine (1R, 2S) - (-)-Ephedrine Disopyramide | 150 6,250 30,000 6,250 KETAMINE (I 100 200 2,000 2,000 2,000 2,000 2,000 2,000 5,000 10,000 2,000 2,000 0XYCODONE | d-Methamphetamine I-Methamphetamine 3,4-Methylendioxymethamphetamine (MDMA) Thioridazine KET 100) Benzphetamine (+) Chlorpheniramine Clonidine EDDP 4-Hydroxyphencyclidine Levorphanol MDE Meperidine d-Methamphetamine I-Methamphetamine Thioridazine 3,4-Methylendioxymethamphetamine (MDMA) (OXY 300) | 15,000 15,000 30,000 15,000 2,000 2,000 10,000 5,000 5,000 5,000 2,000 5,000 5,000 10,000 10,000 |
| Phencyclidine Tetrahydrozoline Mephentermine (1R, 2S) - (-)-Ephedrine Disopyramide Ketamine Dextromethorphan Methoxyphenamine d-Norpropoxyphene Promazine Promethazine Pentazocine Phencyclidine Tetrahydrozoline Mephentermine (1R, 2S) - (-)-Ephedrine Disopyramide Oxycodone | 150 6,250 30,000 6,250 KETAMINE (I 100 200 2,000 2,000 2,000 2,000 2,000 2,000 2,000 10,000 2,000 2,000 0XYCODONE | d-Methamphetamine l-Methamphetamine 3,4-Methylendioxymetham- phetamine (MDMA) Thioridazine KET 100) Benzphetamine (+) Chlorpheniramine Clonidine EDDP 4-Hydroxyphencyclidine Levorphanol MDE Meperidine d-Methamphetamine l-Methamphetamine Thioridazine 3,4-Methylendioxymetham- phetamine (MDMA) (OXY 300) Hydromorphone | 15,000 15,000 30,000 15,000 2,000 2,000 10,000 5,000 5,000 5,000 5,000 5,000 5,000 10,000 10,000 |
| Phencyclidine Tetrahydrozoline Mephentermine (1R, 2S) - (-)-Ephedrine Disopyramide Ketamine Dextromethorphan Methoxyphenamine d-Norpropoxyphene Promazine Promazine Pentazocine Phencyclidine Tetrahydrozoline Mephentermine (1R, 2S) - (-)-Ephedrine Disopyramide Oxycodone Oxymorphone | 150 6,250 30,000 6,250 KETAMINE (I 100 200 2,000 2,000 2,000 2,000 2,000 2,000 2,000 10,000 2,000 0XYCODONE | d-Methamphetamine l-Methamphetamine 3,4-Methylendioxymetham- phetamine (MDMA) Thioridazine KET 100) Benzphetamine (+) Chlorpheniramine Clonidine EDDP 4-Hydroxyphencyclidine Levorphanol MDE Meperidine d-Methamphetamine l-Methamphetamine Thioridazine 3,4-Methylendioxymetham- phetamine (MDMA) (OXY 300) Hydromorphone Naloxone | 15,000 15,000 30,000 15,000 2,000 2,000 10,000 5,000 5,000 5,000 5,000 5,000 5,000 10,000 10,000 150,000 150,000 |
| Phencyclidine Tetrahydrozoline Mephentermine (1R, 2S) - (-)-Ephedrine Disopyramide Ketamine Dextromethorphan Methoxyphenamine d-Norpropoxyphene Promazine Promazine Pentazocine Phencyclidine Tetrahydrozoline Mephentermine (1R, 2S) - (-)-Ephedrine Disopyramide Oxycodone Oxymorphone Levorphanol | 150 6,250 30,000 6,250 KETAMINE (I 100 200 2,000 2,000 2,000 2,000 2,000 2,000 10,000 2,000 0 2,000 0 0 0 0 0 0 0 0 0 0 | d-Methamphetamine I-Methamphetamine 3,4-Methylendioxymethamphetamine (MDMA) Thioridazine KET 100) Benzphetamine (+) Chlorpheniramine Clonidine EDDP 4-Hydroxyphencyclidine Levorphanol MDE Meperidine d-Methamphetamine I-Methamphetamine Thioridazine 3,4-Methylendioxymethamphetamine (MDMA) (OXY 300) Hydromorphone Naloxone | 15,000 15,000 30,000 15,000 2,000 2,000 10,000 5,000 5,000 5,000 5,000 5,000 5,000 10,000 10,000 150,000 150,000 |
| Phencyclidine Tetrahydrozoline Mephentermine (1R, 2S) - (-)-Ephedrine Disopyramide Ketamine Dextromethorphan Methoxyphenamine d-Norpropoxyphene Promazine Promazine Phencyclidine Tetrahydrozoline Mephentermine (1R, 2S) - (-)-Ephedrine Disopyramide Oxycodone Oxymorphone Levorphanol Hydrocodone | 150 6,250 30,000 6,250 KETAMINE (I 100 200 2,000 2,000 2,000 2,000 2,000 2,000 10,000 2,000 0XYCODONE 300 0XYCODONE | d-Methamphetamine I-Methamphetamine 3,4-Methylendioxymethamphetamine (MDMA) Thioridazine KET 100) Benzphetamine (+) Chlorpheniramine Clonidine EDDP 4-Hydroxyphencyclidine Levorphanol MDE Meperidine d-Methamphetamine I-Methamphetamine Thioridazine 3,4-Methylendioxymethamphetamine (MDMA) (OXY 300) Hydromorphone Naloxone Naltrexone (OXY 100) | 15,000 15,000 30,000 15,000 2,000 2,000 10,000 5,000 5,000 5,000 5,000 10,000 10,000 10,000 10,000 10,000 10,000 |
| Phencyclidine Tetrahydrozoline Mephentermine (1R, 2S) - (-)-Ephedrine Disopyramide Ketamine Dextromethorphan Methoxyphenamine d-Norpropoxyphene Promazine Promethazine Pentazocine Phencyclidine Tetrahydrozoline Mephentermine (1R, 2S) - (-)-Ephedrine Disopyramide Oxycodone Oxymorphone Levorphanol Hydrocodone Oxycodone Oxycodone | 150 6,250 30,000 6,250 KETAMINE (I 100 200 2,000 2,000 2,000 2,000 2,000 2,000 10,000 2,000 0XYCODONE 100 0XYCODONE | d-Methamphetamine I-Methamphetamine 3,4-Methylendioxymethamphetamine (MDMA) Thioridazine KET 100) Benzphetamine (+) Chlorpheniramine Clonidine EDDP 4-Hydroxyphencyclidine Levorphanol MDE Meperidine d-Methamphetamine I-Methamphetamine Thioridazine 3,4-Methylendioxymethamphetamine (MDMA) (OXY 300) Hydromorphone Naltrexone (OXY 100) Hydromorphone | 15,000 15,000 30,000 15,000 2,000 2,000 10,000 5,000 5,000 5,000 5,000 10,000 10,000 5,000 |
| Phencyclidine Tetrahydrozoline Mephentermine (1R, 2S) - (-)-Ephedrine Disopyramide Ketamine Dextromethorphan Methoxyphenamine d-Norpropoxyphene Promazine Promethazine Pentazocine Phencyclidine Tetrahydrozoline Mephentermine (1R, 2S) - (-)-Ephedrine Disopyramide Oxycodone Oxymorphone Levorphanol Hydrocodone Oxycodone Oxycodone Oxycodone Oxycodone Oxycodone | 150 6,250 30,000 6,250 KETAMINE (I 100 200 2,000 2,000 2,000 2,000 2,000 2,000 10,000 2,000 0XYCODONE 100 300 | d-Methamphetamine I-Methamphetamine 3,4-Methylendioxymethamphetamine (MDMA) Thioridazine KET 100) Benzphetamine (+) Chlorpheniramine Clonidine EDDP 4-Hydroxyphencyclidine Levorphanol MDE Meperidine d-Methamphetamine I-Methamphetamine Thioridazine 3,4-Methylendioxymethamphetamine (MDMA) (OXY 300) Hydromorphone Naloxone Naltrexone (OXY 100) Hydromorphone Naloxone | 15,000 15,000 30,000 15,000 2,000 10,000 5,000 5,000 5,000 5,000 10,000 10,000 15,000 |
| Phencyclidine Tetrahydrozoline Mephentermine (1R, 2S) - (-)-Ephedrine Disopyramide Ketamine Dextromethorphan Methoxyphenamine d-Norpropoxyphene Promazine Promethazine Pentazocine Phencyclidine Tetrahydrozoline Mephentermine (1R, 2S) - (-)-Ephedrine Disopyramide Oxycodone Oxymorphone Levorphanol Hydrocodone Oxycodone Oxycodone | 150 6,250 30,000 6,250 KETAMINE (I 100 200 2,000 2,000 2,000 2,000 2,000 2,000 10,000 2,000 0XYCODONE 100 0XYCODONE | d-Methamphetamine I-Methamphetamine 3,4-Methylendioxymethamphetamine (MDMA) Thioridazine KET 100) Benzphetamine (+) Chlorpheniramine Clonidine EDDP 4-Hydroxyphencyclidine Levorphanol MDE Meperidine d-Methamphetamine I-Methamphetamine Thioridazine 3,4-Methylendioxymethamphetamine (MDMA) (OXY 300) Hydromorphone Naltrexone (OXY 100) Hydromorphone | 15,000 15,000 30,000 15,000 2,000 2,000 10,000 5,000 5,000 5,000 5,000 10,000 10,000 5,000 |

| | COTININE (| (COT 300) | |
|---|-------------------------------|---|----------|
| (-)-Cotinine | 300 | (-)-Nicotine | 7,500 |
| · | COTININE (| (COT 200) | |
| (-)-Cotinine | 200 | (-)-Nicotine | 5,000 |
| | COTININE (| | |
| (-)-Cotinine | 100 | (-)-Nicotine | 2,500 |
| | COTININE (| · , , , | |
| (-)-Cotinine | 500 | (-)-Nicotine | 12,500 |
| () = | COTININE | <u>', '</u> | T |
| (-)-Cotinine | 50 | (-)-Nicotine | 1,250 |
| () O-ti-i | COTININE | <u>', '</u> | 050 |
| (-)-Cotinine | 10 | (-)-Nicotine IPHENYLPYRROLIDINE (EDI | 250 |
| 2-Ethylidene-1,5-dimethyl-3,3-di | | <u>'</u> | 300 |
| | | PHENYLPYRROLIDINE (EDI | |
| 2-Ethylidene-1,5-dimethyl-3,3-di | | | 100) |
| z-Ettiyilderie-1,3-dimettiyi-3,3-di | FENTANYL | , | 100 |
| Alfentanyl | >600,000 | Buspirone | 80,000 |
| Norfentanyl | 60 | Fentanyl | 300 |
| Fenfluramine | 150,000 | Sufentanyl | 150,000 |
| ormalamine | FENTANYL | | 100,000 |
| Alfentanyl | >600,000 | Buspirone | 30,000 |
| Fenfluramine | 100,000 | Fentanyl | 200 |
| Norfentanyl | 40 | Sufentanyl | 100,000 |
| | FENTANYL | | . 00,000 |
| Alfentanyl | 600,000 | Buspirone | 15,000 |
| Fenfluramine | 50,000 | Fentanyl | 100 |
| Norfentanyl | 20 | Sufentanyl | 50,000 |
| | FENTANYL | | 130,000 |
| Alfentanyl | 600,000 | Buspirone | 15,000 |
| Fenfluramine | 50,000 | Fentanyl | 100 |
| Norfentanyl | 20 | Sufentanyl | 50,000 |
| paliperidone | 1,250 | Risperidone | 5,000 |
| | FENTANYL | | 1.7 |
| Alfentanyl | 300,000 | Buspirone | 8,000 |
| Fenfluramine | 25,000 | Fentanyl | 50 |
| Norfentanyl | 10 | Sufentanyl | 25,000 |
| paliperidone | 500 | Risperidone | 2,500 |
| | | IJUANA (K2-50) | • |
| JWH-018 5-Pentanoic acid | 50 | JWH-073 4-butanoic acid | 50 |
| JWH-018 4-Hydroxypentyl | 400 | JWH-018 5-Hydroxypentyl | 500 |
| JWH-073 4-Hydroxybuty | 500 | | |
| | NTHETIC MAR | IJUANA (K2-30) | • |
| JWH-018 5-Pentanoic acid | 30 | JWH-073 4-butanoic acid | 30 |
| JWH-018 4-Hydroxypentyl | 250 | JWH-018 5-Hydroxypentyl | 300 |
| JWH-073 4-Hydroxybuty | 300 | | |
| SY | NTHETIC MAR | IJUANA (K2-25) | |
| JWH-018 5-Pentanoic acid | 25 | JWH-073 4-butanoic acid | 25 |
| JWH-018 4-Hydroxypentyl | 200 | JWH-018 5-Hydroxypentyl | 250 |
| JWH-073 4-Hydroxybuty | 250 | | |
| 6-MOI | NOACETYLMOI | RPHINE (6-MAM 10) | |
| 6-Monoacethylmorphine | 10 | Morphine | 100,000 |
| (±) 3, 4-METI | IYLENEDIOXY | AMPHETAMINE (MDA 500) | |
| (±) 3,4-Methylenedioxy | | Methoxyphenamine | 6,000 |
| amphetamine | 500 | D-Amphetamine | 2,000 |
| | | Phentermine | 1,000 |
| D,L-Amphetamine sulfate | 300 | Homomino | |
| D,L-Amphetamine sulfate L-Amphetamine | 300 25,000 | Maprotiline | 50,000 |
| L-Amphetamine | 25,000 | | 50,000 |
| L-Amphetamine ETH | 25,000 | Maprotiline | 50,000 |
| L-Amphetamine | 25,000 YL-β-D-GLUCU | Maprotiline RONIDE (ETG 300) | 1 |
| L-Amphetamine ETH Ethyl- β -D-Glucuronide | 25,000 YL-β-D-GLUCU 300 | Maprotiline RONIDE (ETG 300) Propyl β-D-glucuronide | 30,000 |

| ETH | YL-β-D-GLUCU | IRONIDE (ETG 500) | |
|---|--|--|---|
| Ethyl- β -D-Glucuronide | 500 | Propyl β-D-glucuronide | 50,000 |
| Morphine 3β-glucuronide | 100,000 | Morphine 6β-glucuronide | 100,000 |
| Glucuronic Acid | 100,000 | Ethanol | >100,000 |
| Methanol | >100,000 | | |
| | /L-β-D-GLUCUI | RONIDE (ETG 1,000) | |
| Ethyl- β -D-Glucuronide | 1,000 | Propyl β-D-glucuronide | 100,000 |
| Morphine 3β-glucuronide | >100,000 | Morphine 6β-glucuronide | >100,000 |
| Glucuronic Acid | >100,000 | Ethanol | >100,000 |
| Methanol | >100,000 | | |
| | | RONIDE (ETG 1,500) | 1 |
| Ethyl- β -D-Glucuronide | 1,500 | Propyl β-D-glucuronide | 150,000 |
| Morphine 3β-glucuronide | >100,000 | Morphine 6β-glucuronide | >100,000 |
| Glucuronic Acid | >100,000 | Ethanol | >100,000 |
| Methanol | >100,000 | M (0) 0 400) | |
| 21 | CLONAZEPA | <u>'</u> | 000 |
| Clonazepam | 400 | Flunitrazepam | 300 |
| Alprazolam | 200 | (±) Lorazepam | 1,250 |
| a-hydroxyalprazolam | 2,000 | RS-Lorazepamglucuronide | 250 |
| Bromazepam Chlordiazopovida | 1,000 | Midazolam | 5,000 |
| Chlordiazepoxide | 1,000 | Nitrazepam | 200 |
| Clobazam Clorazepatedipotassium | 250 | Norchlordiazepoxide | 1.000 |
| | 600 | Nordiazepam | , |
| Delorazepam | 1,000 250 | Oxazepam Temazepam | 350 150 |
| Desalkylflurazepam Diazepam | 300 | Triazolam | 5,000 |
| Estazolam | 1,250 | IIIazoiaiii | 5,000 |
| _StazOlaili | CLONAZEPA | M (CL O 150) | |
| Clonazepam | 150 | Flunitrazepam | 120 |
| Alprazolam | 75 | (±) Lorazepam | 500 |
| a-hydroxyalprazolam | 750 | RS-Lorazepamglucuronide | 100 |
| Bromazepam | 400 | Midazolam | 2,000 |
| Chlordiazepoxide | 400 | Nitrazepam | 75 |
| Clobazam | 100 | Norchlordiazepoxide | 75 |
| Clorazepatedipotassium | 250 | Nordiazepam | 400 |
| Delorazepam | 400 | Oxazepam | 130 |
| Desalkylflurazepam | 100 | Temazepam | 60 |
| Diazepam | 120 | Triazolam | 2,000 |
| Estazolam | 500 | | ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,, |
| | | THYLAMIDE (LSD 10) | 1 |
| ysergic Acid Diethylamide | 10 | | |
| LYSEF | RGIC ACID DIE | THYLAMIDE (LSD 20) | |
| ysergic Acid Diethylamide | 20 | | |
| LYSEF | RGIC ACID DIE | THYLAMIDE (LSD 50) | • |
| Lysergic Acid Diethylamide | | | |
| | 50 | | |
| | | DATE (MPD 300) | |
| | | | 1,000 |
| Methylphenidate (Ritalin) | METHYLPHENIC 300 | DATE (MPD 300) | 1,000 |
| Methylphenidate (Ritalin) | METHYLPHENIC 300 | DATE (MPD 300) Ritalinic Acid | 1,000 |
| Methylphenidate (Ritalin) Methylphenidate (Ritalin) | 300 METHYLPHENIC METHYLPHENIC 150 | DATE (MPD 300) Ritalinic Acid DATE (MPD 150) | 1 |
| Methylphenidate (Ritalin) Methylphenidate (Ritalin) Methylphenidate (Ritalin) | 300 METHYLPHENIC METHYLPHENIC 150 | DATE (MPD 300) Ritalinic Acid DATE (MPD 150) Ritalinic Acid | 1 |
| Methylphenidate (Ritalin) Methylphenidate (Ritalin) Methylphenidate (Ritalin) | METHYLPHENIC 300 METHYLPHENIC 150 ETHYLPHENID | DATE (MPD 300) Ritalinic Acid DATE (MPD 150) Ritalinic Acid ATE (MPD 1,000) Ritalinic Aicd | 500 |
| Methylphenidate (Ritalin) Methylphenidate (Ritalin) Methylphenidate (Ritalin) Methylphenidate (Ritalin) | METHYLPHENIC 300 METHYLPHENIC 150 ETHYLPHENID 350 | DATE (MPD 300) Ritalinic Acid DATE (MPD 150) Ritalinic Acid ATE (MPD 1,000) Ritalinic Aicd | 500 |
| Methylphenidate (Ritalin) Methylphenidate (Ritalin) Methylphenidate (Ritalin) Methylphenidate (Ritalin) | METHYLPHENIE 300 METHYLPHENIE 150 ETHYLPHENID 350 ZOLPIDEN | PATE (MPD 300) Ritalinic Acid DATE (MPD 150) Ritalinic Acid ATE (MPD 1,000) Ritalinic Aicid M (ZOL 50) | 500 |
| Methylphenidate (Ritalin) Methylphenidate (Ritalin) Methylphenidate (Ritalin) Methylphenidate (Ritalin) Zolpidem | METHYLPHENIE 300 METHYLPHENIE 150 ETHYLPHENID 350 ZOLPIDEN | PATE (MPD 300) Ritalinic Acid DATE (MPD 150) Ritalinic Acid ATE (MPD 1,000) Ritalinic Aicid M (ZOL 50) | 500 |
| Methylphenidate (Ritalin) Methylphenidate (Ritalin) Methylphenidate (Ritalin) Methylphenidate (Ritalin) Zolpidem | METHYLPHENIC 300 METHYLPHENIC 150 ETHYLPHENID 350 ZOLPIDEN 50 ZOLPIDEN | PATE (MPD 300) Ritalinic Acid DATE (MPD 150) Ritalinic Acid ATE (MPD 1,000) Ritalinic Acid ATE (MPD 1,000) Ritalinic Aicd M (ZOL 50) M (ZOL 25) | 500 |
| Methylphenidate (Ritalin) Methylphenidate (Ritalin) Methylphenidate (Ritalin) Methylphenidate (Ritalin) Zolpidem Zolpidem | METHYLPHENID 300 METHYLPHENID 150 ETHYLPHENID 350 ZOLPIDEN 50 ZOLPIDEN 25 | PATE (MPD 300) Ritalinic Acid DATE (MPD 150) Ritalinic Acid ATE (MPD 1,000) Ritalinic Acid ATE (MPD 1,000) Ritalinic Aicd M (ZOL 50) M (ZOL 25) | 500 |
| Methylphenidate (Ritalin) Methylphenidate (Ritalin) Methylphenidate (Ritalin) Mothylphenidate (Ritalin) Zolpidem Zolpidem Mephedrone HCI | METHYLPHENID 300 METHYLPHENID 150 ETHYLPHENID 350 ZOLPIDEN 50 ZOLPIDEN 25 MEPHEDRON | PATE (MPD 300) Ritalinic Acid DATE (MPD 150) Ritalinic Acid ATE (MPD 1,000) Ritalinic Acid ATE (MPD 1,000) Ritalinic Aicd M (ZOL 25) M (ZOL 25) ME (MEP 500) | 500 |
| Methylphenidate (Ritalin) Methylphenidate (Ritalin) Methylphenidate (Ritalin) Mothylphenidate (Ritalin) Zolpidem Zolpidem Mephedrone HCl S(-)-Methcathinone HCl | #ETHYLPHENID 300 #ETHYLPHENID 150 ETHYLPHENID 350 ZOLPIDEN 50 ZOLPIDEN 25 MEPHEDRON 500 | PATE (MPD 300) Ritalinic Acid DATE (MPD 150) Ritalinic Acid ATE (MPD 1,000) Ritalinic Acid ATE (MPD 1,000) Ritalinic Aicd M (ZOL 50) M (ZOL 25) JE (MEP 500) R(+)-Methcathinone HCI | 500 1,000 |
| Methylphenidate (Ritalin) Methylphenidate (Ritalin) Methylphenidate (Ritalin) Mothylphenidate (Ritalin) Zolpidem Zolpidem Mephedrone HCl S(-)-Methcathinone HCl | #ETHYLPHENID 350 #ETHYLPHENID 350 #ETHYLPHENID 350 #ETHYLPHENID 350 #EDLENIDEN 50 ##EPHEDRON 500 2,500 | PATE (MPD 300) Ritalinic Acid DATE (MPD 150) Ritalinic Acid ATE (MPD 1,000) Ritalinic Acid ATE (MPD 1,000) Ritalinic Acid M (ZOL 50) M (ZOL 25) M (ZOL 25) M (XOL 25) | 500 |
| Methylphenidate (Ritalin) Methylphenidate (Ritalin) | ### ALTHYLPHENID 150 20 20 250 2,500 1,500 20 1,500 2,500 1,500 20 2,500 1,500 20 2,500 1,500 20 20 2,500 1,500 20 20 20 20 20 20 20 | PATE (MPD 300) Ritalinic Acid DATE (MPD 150) Ritalinic Acid ATE (MPD 1,000) Ritalinic Acid ATE (MPD 1,000) Ritalinic Acid M (ZOL 50) M (ZOL 25) M (ZOL 25) M (XOL 25) | 500 |

| 4-Fluoromethcathinone HCl | 300 | Methoxyphenamine | 100,000 |
|---------------------------------------|--------------|---|---------|
| 3, 4-METHYLE | NEDIOXYPYRO | VALERONE (MDPV 1,000) | |
| 3, 4-methylenedioxypyrovalerone | 1,000 | | |
| 3, 4-METHYL | ENEDIOXYPYR | OVALERONE (MDPV 500) | |
| 3, 4-methylenedioxypyrovalerone | 500 | | |
| | _ | OVALERONE (MDPV 300) | |
| 3, 4-methylenedioxypyrovalerone | 300 | | |
| | DIAZEPAM (| (DIA 300) | |
| Diazepam | 300 | Midazolam | 6,000 |
| Clobazam | 200 | Nitrazepam | 200 |
| Clonazepam | 500 | Norchlordiazepoxide | 100 |
| Clorazepate dipotassium | 500 | Nordiazepam | 900 |
| Alprazolam | 100 | Flunitrazepam | 200 |
| a-hydroxyalprazolam | 1,500 | (±) Lorazepam | 3,000 |
| Bromazepam | 900 | RS-Lorazepam glucuronide | 200 |
| Chlordiazepoxide | 900 | Triazolam | 3,000 |
| Estazolam | 6,000 | Temazepam | 100 |
| Delorazepam | 900 | Oxazepam | 300 |
| Desalkylflurazepam | 200 | | |
| | DIAZEPAM (| · · · · · · · · · · · · · · · · · · · | 1 |
| Diazepam | 200 | Midazolam | 4,000 |
| Clobazam | 120 | Nitrazepam | 120 |
| Clonazepam | 300 | Norchlordiazepoxide | 70 |
| Clorazepate dipotassium | 300 | Nordiazepam | 600 |
| Alprazolam | 70 | Flunitrazepam | 120 |
| a-hydroxyalprazolam | 1,000 | (±) Lorazepam | 2,000 |
| Bromazepam | 600 | RS-Lorazepam glucuronide | 120 |
| Chlordiazepoxide | 600 | Triazolam | 2,000 |
| Estazolam | 4,000 | Temazepam | 70 |
| Delorazepam | 600 | Oxazepam | 200 |
| Desalkylflurazepam | 120 | | |
| | ZOPICLONE | (ZOP 300) | |
| Zopiclone-x-oxide | 300 | Zopiclone | 300 |
| | ZOPICLONE | · / | |
| Zopiclone-x-oxide | 50 | Zopiclone | 50 |
| | ETHCATHINON | , · · · · · · · · · · · · · · · · · · · | |
| S(-)-Methcathinone HCI | 500 | R(+)-Methcathinone HCI | 1,500 |
| Methoxyphenamine | 100,000 | 3-Fluoromethcathinone HCI | 1,500 |
| 7-AN | IINOCLONAZEF | PAM (7-ACL 300) | |
| a-hydroxyalprazolam | 6,000 | Flunitrazepam | 3,000 |
| Bromazepam | 6,000 | RS-Lorazepam glucuronide | 2,700 |
| Chlordiazepoxide | 6,000 | Norchlordiazepoxide | 4,500 |
| Clobazam | 9,000 | Nordiazepam | 15,000 |
| Clonazepam | 2,400 | Temazepam | 9,000 |
| Delorazepam | 6,000 | 7-Aminoclonazepam | 300 |
| Desalkylflurazepam | 6,000 | | |
| 7-AN | IINOCLONAZEF | PAM (7-ACL 200) | |
| a-hydroxyalprazolam | 4,000 | Flunitrazepam | 2,000 |
| Bromazepam | 4,000 | RS-Lorazepam glucuronide | 1,800 |
| Chlordiazepoxide | 4,000 | Norchlordiazepoxide | 3,000 |
| Clobazam | 6,000 | Nordiazepam | 10,000 |
| Clonazepam | 1,600 | Temazepam | 6,000 |
| Delorazepam | 4,000 | 7-Aminoclonazepam | 200 |
| Desalkylflurazepam | 4,000 | | |
| 7-AN | IINOCLONAZEF | PAM (7-ACL 100) | |
| a-hydroxyalprazolam | 2,000 | Flunitrazepam | 1,000 |
| Bromazepam | 2,000 | RS-Lorazepam glucuronide | 900 |
| Chlordiazepoxide | 2,000 | Norchlordiazepoxide | 1,500 |
| | | Nordiazepam | 5,000 |
| | 3,000 | Nordiazepani | 0,000 |
| Clobazam | 3,000 800 | Temazepam | 3,000 |
| Clobazam Clonazepam Delorazepam | | · · | |

| • | CARFENTANYL | (CFYL 500) | |
|--|--|---|---|
| Carfentanyl | 500 | Fentanyl | 100 |
| Sufentanil | 50,000 | Ramifentanil | 10,000 |
| (±)cis-3-Menthylfentanyl | 20,000 | Butyl fentanyl | 150 |
| C | CARFENTANYL | (CFYL 250) | |
| Carfentanyl | 250 | Fentanyl | 50 |
| Sufentanil | 25,000 | Ramifentanil | 5,000 |
| (±)cis-3-Menthylfentanyl | 10,000 | Butyl fentanyl | 75 |
| | CAFFEINE (C | AF 1,000) | |
| Caffeine | 1,000 | | |
| | CATHINE (C | | |
| (+)-Norpseudoephedrine HCI | 150 | (+)3,4-Methylenedioxyamphe | 100 |
| (Cathine) | | tamine (MDA) | 100 |
| d/I-Amphetamine | 100 | p-Hydroxyamphetamine | 100 |
| Tryptamine | 12,500 | Methoxyphenamine | 12,500 |
| | TROPICAMIDE | (TRO 350) | |
| Tropicamide | 350 | | |
| | ALPRAZOLAM | (ALP 100) | |
| Benzodiazepines | 300 | | 200 |
| a-hydroxyalprazolam | 1,500 | (±) Lorazepam | 3,000 |
| Bromazepam | 900 | · • | 200 |
| Chlordiazepoxide | 900 | | 6,000 |
| Clobazam | 200 | Nitrazepam | 200 |
| Clonazepam | 500 | Norchlordiazepoxide | 100 |
| Clorazepatedipotassium | 500 | Nordiazepam | 900 |
| Delorazepam | 900 | Oxazepam | 300 |
| Desalkylflurazepam | 200 | Temazepam | 100 |
| Diazepam | 300 | Triazolam | 3,000 |
| Estazolam | 6,000 | Alprazolam | 100 |
| F | REGABALIN (I | PGB 50,000) | |
| Pregabalin | 50,000 | | |
| | PREGABALIN | (PGB 500) | |
| Pregabalin | 500 | | |
| | ZALEPLON (| ZAL 100) | |
| Zaleplon | 100 | | |
| | CANNABINOL | (CNB 500) | |
| cannabinol | 500 | Δ ⁹ -THC | 10,000 |
| .9 | 300 | | .0,000 |
| 11-nor-∆° -1HC-9 COOH | 000 | | 10,000 |
| | GABAPENTIN (| GAB 2,000) | 10,000 |
| 11-nor-Δ ⁹ -THC-9 COOH Gabapentin | | GAB 2,000) | 10,000 |
| (| GABAPENTIN (| | 10,000 |
| Gabapentin Trazodone | 2,000 TRAZODONE | (TZD 200) | |
| Gabapentin Trazodone | GABAPENTIN (2,000 TRAZODONE 200 ARISOPRODOL | (TZD 200) | |
| Gabapentin Trazodone CA Carisoprodol | GABAPENTIN (2,000 TRAZODONE 200 ARISOPRODOL 2,000 | (TZD 200) | 10,000 |
| Gabapentin Trazodone CACarisoprodol | GABAPENTIN (2,000 TRAZODONE 200 ARISOPRODOL 2,000 ARISOPRODOL | (TZD 200) | |
| Gabapentin Trazodone Carisoprodol Carisoprodol | GABAPENTIN (2,000 TRAZODONE 200 ARISOPRODOL 2,000 ARISOPRODOL 1,000 | (TZD 200) | |
| Gabapentin Trazodone Carisoprodol Carisoprodol | GABAPENTIN (2,000 TRAZODONE 200 ARISOPRODOL 2,000 ARISOPRODOL | (TZD 200) | |
| Gabapentin Trazodone Carisoprodol Carisoprodol Carisoprodol Carisoprodol | GABAPENTIN (2,000 TRAZODONE 200 ARISOPRODOL 2,000 ARISOPRODOL 1,000 CARISOPRODOL | (TZD 200) (CAR 2,000) (CAR 1,000) (CAR 1,000) (CAR 500) | |
| Gabapentin Trazodone Carisoprodol Carisoprodol Carisoprodol Carisoprodol | GABAPENTIN (2,000 TRAZODONE 200 ARISOPRODOL 1,000 ARISOPRODOL 1,000 500 B-PINACA/K3 | (TZD 200) (CAR 2,000) (CAR 1,000) L (CAR 500) (ABP/K3 10) | |
| Gabapentin Trazodone Carisoprodol Carisoprodol Carisoprodol Carisoprodol AB-PINACA | GABAPENTIN (2,000 TRAZODONE 200 ARISOPRODOL 1,000 ARISOPRODOL 4,000 500 B-PINACA/K3 | (TZD 200) (CAR 2,000) (CAR 1,000) L (CAR 500) (ABP/K3 10) AB-PINACA 5-Pentanoic | 10 |
| Gabapentin Trazodone Carisoprodol Carisoprodol Carisoprodol Carisoprodol AB-PINACA | GABAPENTIN (2,000 TRAZODONE 200 ARISOPRODOL 1,000 ARISOPRODOL 1,000 500 B-PINACA/K3 | (TZD 200) (CAR 2,000) (CAR 1,000) L (CAR 500) (ABP/K3 10) | |
| Gabapentin Trazodone Carisoprodol Carisoprodol Carisoprodol AB-PINACA AB-PINACA 5-hydroxypentyl | GABAPENTIN (2,000 TRAZODONE 200 ARISOPRODOL 1,000 ARISOPRODOL 4,000 500 B-PINACA/K3 | (TZD 200) (CAR 2,000) (CAR 1,000) L (CAR 500) (ABP/K3 10) AB-PINACA 5-Pentanoic | 10 10 5,000 |
| Gabapentin Trazodone Czarisoprodol Carisoprodol Carisoprodol Carisoprodol AB-PINACA AB-PINACA AB-PINACA 4-hydroxypentyl AB-PINACA 4-hydroxypentyl | GABAPENTIN (2,000 TRAZODONE 200 ARISOPRODOL 1,000 ARISOPRODOL 500 B-PINACA/K3 | (TZD 200) (CAR 2,000) (CAR 1,000) L (CAR 500) (ABP/K3 10) AB-PINACA 5-Pentanoic AB-FUBINACA | 10 |
| Gabapentin Trazodone Carisoprodol Carisoprodol Carisoprodol Carisoprodol AB-PINACA AB-PINACA 4-hydroxypentyl AB-PINACA 4-hydroxypentyl UR-144 5-hydroxypentyl | GABAPENTIN (2,000 TRAZODONE 200 ARISOPRODOL 1,000 ARISOPRODOL 1,000 B-PINACA/K3 10 10 10,000 | (TZD 200) (CAR 2,000) (CAR 1,000) L (CAR 500) (ABP/K3 10) AB-PINACA 5-Pentanoic AB-FUBINACA UR-144 5-Pentanoic UR-144 4-hydroxypentyl ADB-PINACA Pentanoic Acid | 10 10 5,000 10,000 |
| Gabapentin Trazodone Carisoprodol Carisoprodol Carisoprodol Carisoprodol AB-PINACA AB-PINACA 5-hydroxypentyl AB-PINACA 4-hydroxypentyl UR-144 5-hydroxypentyl APINACA 5-hydroxypentyl | GABAPENTIN (2,000 TRAZODONE 200 ARISOPRODOL 1,000 ARISOPRODOL 1,000 500 B-PINACA/K3 10 10,000 10,000 10,000 | (TZD 200) (CAR 2,000) (CAR 1,000) L (CAR 500) (ABP/K3 10) AB-PINACA 5-Pentanoic AB-FUBINACA UR-144 5-Pentanoic UR-144 4-hydroxypentyl | 10 10 5,000 10,000 |
| Gabapentin Trazodone Carisoprodol Carisoprodol Carisoprodol Carisoprodol | GABAPENTIN (2,000 TRAZODONE 200 ARISOPRODOL 1,000 ARISOPRODOL 1,000 500 B-PINACA/K3 10 10,000 10,000 10,000 | (TZD 200) (CAR 2,000) (CAR 1,000) L (CAR 500) L (CAR 500) AB-PINACA 5-Pentanoic AB-FUBINACA BF-144 5-Pentanoic UR-144 4-hydroxypentyl ADB-PINACA Pentanoic Acid 5-fluoro AB-PINACA | 10 10 5,000 10,000 |
| Gabapentin Trazodone Carisoprodol Carisoprodol Carisoprodol AB-PINACA AB-PINACA 5-hydroxypentyl AB-PINACA 4-hydroxypentyl AR-144 5-hydroxypentyl APINACA 5-hydroxypentyl APINACA 5-hydroxypentyl | GABAPENTIN (2,000 TRAZODONE 200 ARISOPRODOL 1,000 ARISOPRODOL 1,000 B-PINACA/K3 1 10 10,000 10,000 30 | (TZD 200) (CAR 2,000) (CAR 1,000) L (CAR 500) L (CAR 500) AB-PINACA 5-Pentanoic AB-PIBINACA UR-144 5-Pentanoic UR-144 4-hydroxypentyl ADB-PINACA Pentanoic Acid 5-fluoro AB-PINACA N-(4-hydroxypentyl) | 10 10 5,000 10,000 |
| Gabapentin Trazodone Carisoprodol Carisoprodol Carisoprodol Carisoprodol AB-PINACA AB-PINACA 5-hydroxypentyl AB-PINACA 4-hydroxypentyl APINACA 5-hydroxypentyl APINACA 5-hydroxypentyl APINACA 5-hydroxypentyl | GABAPENTIN (2,000 TRAZODONE 200 ARISOPRODOL 1,000 ARISOPRODOL 1,000 ARISOPRODOL 10,000 10,000 10,000 10,000 30 25 | (TZD 200) (CAR 2,000) (CAR 1,000) L (CAR 500) L (CAR 500) AB-PINACA 5-Pentanoic AB-PIBINACA UR-144 5-Pentanoic UR-144 4-hydroxypentyl ADB-PINACA Pentanoic Acid 5-fluoro AB-PINACA N-(4-hydroxypentyl) | 10 10 5,000 10,000 |
| Gabapentin Trazodone Carisoprodol Carisoprodol Carisoprodol Carisoprodol AB-PINACA AB-PINACA 4-hydroxypentyl AB-PINACA 4-hydroxypentyl UR-144 5-hydroxypentyl APINACA 5-hydroxypentyl APINACA 5-hydroxypentyl APINACA 5-hydroxypentyl APINACA 5-hydroxypentyl ADB-PINACA N-(5-hydroxypentyl) 5-fluoro AB-PINACA | GABAPENTIN (2,000 TRAZODONE 200 ARISOPRODOL 1,000 ARISOPRODOL 1,000 B-PINACA/K3 10 10,000 10,000 10,000 30 25 UR-144/K | (TZD 200) (CAR 2,000) (CAR 1,000) L (CAR 500) L (CAR 500) AB-PINACA 5-Pentanoic AB-FUBINACA UR-144 5-Pentanoic UR-144 4-hydroxypentyl ADB-PINACA Pentanoic Acid 5-fluoro AB-PINACA N-(4-hydroxypentyl) 4 (25) | 10 10 5,000 10,000 10 |
| Gabapentin Trazodone Carisoprodol Carisoprodol Carisoprodol Carisoprodol AB-PINACA AB-PINACA 5-hydroxypentyl AB-PINACA 4-hydroxypentyl UR-144 5-hydroxypentyl APINACA 5-hydroxypentyl APINACA 5-hydroxypentyl ADB-PINACA N-(5-hydroxypentyl) 5-fluoro AB-PINACA | GABAPENTIN (2,000 TRAZODONE 200 ARISOPRODOL 1,000 500 B-PINACA/K3 10 10,000 10,000 10,000 25 UR-144/K 25 | (TZD 200) (CAR 2,000) (CAR 1,000) L (CAR 500) L (CAR 500) AB-PINACA 5-Pentanoic AB-FUBINACA UR-144 4-hydroxypentyl ADB-PINACA Pentanoic Acid 5-fluoro AB-PINACA N-(4-hydroxypentyl) 4 (25) UR-144 4-hydroxypentyl | 10 10 5,000 10,000 10 30 |

| | QUETIAPINE (| QTP 1,000) | |
|----------------------------------|------------------|--------------------------------------|-----------|
| Quetiapine | 1,000 | Norquetiapine | 10,000 |
| | FLUOXETINE | (FLX 500) | |
| Fluoxetine | 500 | | |
| | KRATOM (K | (RA 300) | |
| Mitragynine | 300 | 7-hydroxymitragynine | >50,000 |
| | TILIDINE (1 | TLD 50) | |
| Nortilidine | 50 | Tilidine | 100 |
| ALPHA-PYRROLID | INOVALEROPI | HENONE (α-PVP 2,000) | |
| Alpha-Pyrrolidinovalerophenone | 2,000 | | |
| ALPHA-PYRRO | LIDINOVALER | OPHENONE (α-PVP 1,000) | |
| Alpha-Pyrrolidinovalerophenone | 1,000 | | |
| ALPHA-PYRR | OLIDINOVALER | ROPHENONE (α-PVP 500) | |
| Alpha-Pyrrolidinovalerophenone | 500 | | |
| ALPHA-PYRROLI | DINOVALEROF | PHENONE (α-PVP 300) | |
| Alpha-Pyrrolidinovalerophenone | 300 | | |
| MI | SCALINE (ME | S 100) | |
| Mescaline | 100 | | |
| MI | SCALINE (ME | S 300) | |
| Mescaline | 300 | | |
| PA | PAVERINE (PA | AP 500) | |
| Papaverine | 500 | Diflunisal | 1,000,000 |
| Methortrexate | 65,000 | Methedrone | 500,000 |
| Pragablin | 500,000 | Phenelzine | 8,000 |
| Quinine | 4,000 | | |
| | ENTADOL (TA | P 1,000) | |
| 3-((1R,2R)-3-(dimethylamino)-1- | 1,000 | | |
| ethyl-2-methylpropyl)phenol | | | |
| | CITALOPRAN | (CIT 500) | 1 |
| Desmethylcitalopram | 500 | | |
| | F-KETAMINE (F | KET 1,000) | 1 |
| 2-(2-fluorphenyl)-2-methylamino- | 1,000 | | |
| cyclohexanone | | | |
| · · · · | RISPERIDONE | (RPD 150) | 1 |
| Risperidone | 150 | (2227.522) | |
| | COPOLAMINE | i i | 0.000 |
| Scopolamine | 500 | Atropine | 3,000 |
| | | AMINE (NND 1,000) | 1 |
| N, N-Dimethyltryptamine | 1,000 | T7 500) | |
| | RTAZAPINE (M | , | Ison |
| N-Desmethylmirtazapine | 500 | Mirtazapine | 500 |
| | NZAPINE (OZ | P 1,000) | 1 |
| Olanzapine | 1,000 | (11140 500) | |
| | OMORPHONE | ` | 000 |
| Hydromorphone | 500 | Morphine | 200 |
| Codeine | 120 | Ethylmorphine | 120 |
| Hydrocodone | 500 | Morphine | 250 |
| a varah an al | 0.000 | 3-β-D-Glucuronide | 105.000 |
| _evorphanol | 2,000 | Oxycodone | 125,000 |
| Normorphine | 125,000 | Norcodeine | 31,200 |
| Oxymorphone Thebaine | 125,000 | Nalorphine | 50,000 |
| | 10,000 | Diacetylmorphine (Heroin) | 250 |
| 6-Monoacetylmorphine | 120 | (LIMO 200) | 1 |
| | OMORPHONE | | 400 |
| Hydromorphone | 300 | Morphine Ethylmorphine | 120 |
| Codeine | 75 | Ethylmorphine Morphine | 75 |
| Hydrocodone | 300 | Morphine | 150 |
| overshand | 1 200 | 3-β-D-Glucuronide | 75 000 |
| _evorphanol Normorphine | 1,200 | Oxycodone Norcodeine | 75,000 |
| Normorphine Oxymorphone | 75,000 75,000 | | 18,700 |
| • | 75,000 | Nalorphine Diacetylmorphine (Heroin) | 30,000 |
| Fhebaine 6-Monoacetylmorphine | 6,000 | Diacetylinorphiline (meroln) | 150 |
| z-wonoacetymorphine | 75 | 1 | 1 |

| HYDROMORPHONE (HMO 250) | | | |
|-------------------------|--------|-------------------------------|--------|
| Hydromorphone | 250 | Morphine | 100 |
| Codeine | 60 | Ethylmorphine | 60 |
| Hydrocodone | 250 | Morphine 3-β-D-Glucuronide | 125 |
| Levorphanol | 1,000 | Oxycodone | 62,500 |
| Normorphine | 62,500 | Norcodeine | 15,600 |
| Oxymorphone | 62,500 | Nalorphine | 25,000 |
| Thebaine | 5,000 | Diacetylmorphine (Heroin) | 125 |
| 6-Monoacetylmorphine | 60 | | |

Effect of Urinary Specific Gravity

Fifteen (15) urine samples of normal, high, and low specific gravity ranges (1.005-1.045) were spiked with drugs at 50% below and 50% above cut-off levels respectively. The Multi-Drug Rapid Test was tested in duplicate using fifteen drug-free urine and spiked urine samples. The results demonstrate that varying ranges of urinary specific gravity do not affect the test results.

Effect of Urinary pH

The pH of an aliquoted negative urine pool was adjusted to a pH range of 5 to 9 in 1 pH unit increments and spiked with drugs at 50% below and 50% above cut-off levels. The spiked, pH-adjusted urine was tested with the Multi-Drug Rapid Test. The results demonstrate that varying ranges of pH do not interfere with the performance of the test.

Cross-Reactivity

A study was conducted to determine the cross-reactivity of the test with compounds in either drug-free urine or drug positive urine containing above related calibrator substances. The following compounds show no cross-reactivity when tested with the Multi-Drug Rapid Test at a concentration of 100 μ g/mL.

Non Cross-Reacting Compounds

| | | ang compounds | |
|----------------------|------------------------|----------------|----------------------|
| Acetophenetidin | Cortisone | Zomepirac | Quinidine |
| N-Acetylprocainamide | Creatinine | Ketoprofen | Quinine |
| Acetylsalicylic acid | Deoxycorticosterone | Labetalol | Salicylic acid |
| Aminopyrine | Dextromethorphan | Loperamide | Serotonin |
| Amoxicillin | Diclofenac | Meprobamate | Sulfamethazine |
| Ampicillin | Diflunisal | Isoxsuprine | Sulindac |
| I-Ascorbic acid | Digoxin | d,I-Propanolol | Tetracycline |
| Apomorphine | Diphenhydramine | Nalidixic acid | Tetrahydrocortisone, |
| Aspartame | Ethyl-p-aminobenzoate | Naproxen | 3-acetate |
| Atropine | β-Estradiol | Niacinamide | Tetrahydrocortisone |
| Benzilic acid | Estrone-3-sulfate | Nifedipine | Tetrahydrozoline |
| Benzoic acid | Erythromycin | Norethindrone | Thiamine |
| Bilirubin | Fenoprofen | Noscapine | Thioridazine |
| d,I-Brompheniramine | Furosemide | d,I-Octopamine | d,I-Tyrosine |
| Cannabidiol | Gentisic acid | Oxalic acid | Tolbutamide |
| Chloral hydrate | Hemoglobin | Oxolinic acid | Triamterene |
| Chloramphenicol | Hydralazine | Oxymetazoline | Trifluoperazine |
| Chlorothiazide | Hydrochlorothiazide | Penicillin-G | Trimethoprim |
| d,l-Chlorpheniramine | Hydrocortisone | Perphenazine | d,I-Tryptophan |
| Chlorpromazine | o-Hydroxyhippuric acid | Phenelzine | Uric acid |
| Cholesterol | 3-Hydroxytyramine | Prednisone | Verapamil |
| Clonidine | d,l-Isoproterenol | | |

[ALCOHOL PERFORMANCE CHARACTERISTICS]

The detection limit on the **Urine Alcohol Rapid Test** is from 0.02% to 0.30% for approximate relative blood alcohol level. The cutoff level of the **Urine Alcohol Rapid Test** can vary based on local regulations and laws. Test results can be compared to reference levels with color chart on the foil package.

[ALCOHOL ASSAY SPECIFICITY]

The Urine Alcohol Rapid Test will react with methyl, ethyl and allyl alcohols.

[ALCOHOL INTERFERING SUBSTANCES]

The following substances may interfere with the **Urine Alcohol Rapid Test** when using samples other than urine. The named substances do not normally appear in sufficient quantity in urine to interfere with the test.

- A. Agents which enhance color development
 - Peroxidases

- Strong oxidizers
- B. Agents which inhibit color development
 - Reducing agents: Ascorbic acid, Tannic acid, Pyrogallol, Mercaptans and tosylates, Oxalic acid, Uric Acid
 - Bilirubin

- L-dopa
- L-methyldopa
 Methampyrone

[BIBLIOGRAPHY]

- 1. Tietz NW. Textbook of Clinical Chemistry. W.B. Saunders Company. 1986; 1735.
- 2. B. Cody, J.T., "Specimen Adulteration in drug urinalysis. Forensic Sci. Rev., 1990, 2:63.
- 3. C. Tsai, S.C. et.al., J. Anal. Toxicol. 1998; 22 (6): 474
- Hawks RL, CN Chiang. Urine Testing for Drugs of Abuse. National Institute for Drug Abuse (NIDA),Research Monograph 73, 1986.
- Baselt RC. Disposition of Toxic Drugs and Chemicals in Man. 6th Ed. Biomedical Publ., Foster City,CA 2002.



Number: 14601144101 Revision date: 2023-09-21